CUMULATIVE SUPPLEMENT 11

JAN'88-NOV'88

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

8TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT

SUBSCRIBE NOW!

Available in March 1989

New 9th Edition



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

9TH EDITION
1989

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- List of Drug Products Approved Under Section 505 of the Act by the Division of Blood and Blood Products
- Discontinued Drug Product List
- Orphan Drug Products with Exclusive Approval
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS

with

THERAPEUTIC EQUIVALENCE EVALUATIONS

8TH EDITION

CUMULATIVE SUPPLEMENT 11

NOVEMBER 1988

CONTENTS

APPROVED DRUG PRODUCTS

with

THERAPEUTIC EQUIVALENCE EVALUATIONS

8th EDITION

CUMULATIVE SUPPLEMENT 11

NOVEMBER 1988

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 8th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products in the Division of Blood and Blood Products approved under Section 505 of the Act, and products discontinued from marketing or products which have had their approval withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product, along with the application number and product number (FDA's internal file number). All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.] The effective date for the approved drug product (the earliest date a product may be marketed) appears, when appropriate, to the left of the approval date.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge ( ) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line containing overstruck print. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print will remain in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data will be dropped in subsequent Cumulative Supplements.

Products discontinued from marketing or products which have had their approval withdrawn for other than safety or effectiveness reasons, will be flagged in this Cumulative Supplement with the " ə " symbol to designate their non-marketed status. All products having a " ə " symbol in the 12th Cumulative Supplement of the 8th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 9th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.3 APPLICANT (NAME) CHANGES

Because it is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT (NAME) CHANGES

FORMER APPLICANT (NAME)	NEW APPLICANT (NAME)	NEW ABBREVIATED NAME
AYERST LABORATORIES INC DIV AMERICAN HOME PRODUCTS CORP	WYETH AYERST LABORATORIES INC	WYETH AYERST LABS
NOVOCOL CHEMICAL MANUFACTURING COMPANY INC	NOVOCOL PHARMACEUTICAL INC	NOVOCOL PHARM
WYETH INC	WYETH AYERST LABORATORIES INC	WYETH AYERST LABS
WYETH LABORATORIES INC	WYETH AYERST LABORATORIES INC	WYETH AYERST LABS
MY K LABORATORIES INC	PHARMACEUTICAL BASICS INC	PHARM BASICS

1.4 TRAZODONE HYDROCHLORIDE

Generic Trazodone HCl 150mg tablet entries, marked with a ( ), are rated as therapeutically equivalent (AB) to Mead Johnson's Desyrel (Trazodone HCl) Dividose 150mg tablets. The therapeutic equivalence determination, among other things, was made on the basis of an acceptable bioequivalence study and acceptable in vitro dissolution testing. A patent that exists on the Desyrel 150mg tablet scoring design, which enables the patient to break Desyrel into three 50mg segments, prevents a generic firm from copying this feature. Therefore, a patient will not be able to obtain three 50mg segments from the generic tablet. Prescribers and dispensers should be aware of this difference and take it into account when writing a prescription or practicing drug product selection.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1987) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product, provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

COUNTS CUMULATIVE BY QUARTER[1]

CATEGORIES COUNTED	DEC 1987	MAR 1988	JUN 1988	SEP 1988
DRUG PRODUCTS LISTED	9709	9528	9769	9993*
SINGLE SOURCE	2096 (21.6%)	1997 (21.0%)	1975 (20.2%)	1973 (19.7%)
MULTISOURCE	7613 (78.4%)	7531 (79.0%)	7794 (79.8%)	8020 (80.3%)
THERAPEUTICALLY EQUIVALENT	6691 (68.9%)	6660 (69.9%)	6937 (71.0%)	7161 (71.7)
NOT THERAPEUTICALLY EQUIVALENT	848 (8.7%)	770 (8.1%)	757 (7.8%)	749 (7.5)
EXCEPTIONS[2]	74 (0.8%)	101 (1.0)	100 (1.0%)	110 (1.1)
NEW MOLECULAR ENTITIES APPROVED	--	1	2	3
NUMBER OF APPLICANTS	349	361	378	387

*This number is inclusive of products discontinued since December 1987, and any products approved or discontinued through September 1988.

[1]Cumulative counts are calculated from January 1, 1988 to, and including, the month indicated.
[2]Amino acid-containing products of varying composition (see Introduction, page 1-8 of the List).

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

AB	HALSEY DRUG	325MG;50MG		N89568 001 OCT 05, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	MIKART	500MG;50MG;40MG		N89451 001 MAY 23, 1988

BUTALBITAL, APAP, AND CAFFEINE

AB	HALSEY DRUG	325MG;50MG;40MG		N89536 001 FEB 16, 1988

ACETAMINOPHEN; CODEINE PHOSPHATE

ELIXIR; ORAL

MYAPAP AND CODEINE

AA	MY K LABS	120MG/5ML;12MG/5ML		N87006 001

MYAPAP W/ CODEINE

/AA/	/MYKLABS/	/120MG/5ML;12MG/5ML/		/N87006/001/

TYLENOL W/ CODEINE

/AA/	/MCNEIL/LABS/	/120MG/5ML;12MG/5ML/		/N85057/001/
AA	MCNEIL PHARM	120MG/5ML;12MG/5ML		N85057 001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	BARR LABS	300MG;30MG		N85794 001
/AA/	/BARR/LABS/	/300MG;30MG/		/N85794/001/
AA	CHARLOTTE PHARM	300MG;15MG		N89990 001 SEP 30, 1988
AA		300MG;30MG		N89805 001 SEP 30, 1988
AA		300MG;60MG		N89828 001 SEP 30, 1988
AA	HALSEY DRUG	300MG;60MG		N86549 001
AA	MUTUAL PHARM	300MG;15MG		N89671 001 FEB 10, 1988
AA		300MG;30MG		N89672 001 FEB 10, 1988
AA		300MG;60MG		N89673 001 FEB 10, 1988
AA	PHARMAFAIR	300MG;30MG		N87762 001 DEC 10, 1982

ACETAMINOPHEN W/ CODEINE

/AA/	/BARR/LABS/	/300MG;30MG/		/N85794/001/

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

/ACETAMINOPHEN W/ CODEINE PHOSPHATE/

/AA/	/HALSEY/DRUG/	/300MG;60MG/		/N86549/001/

TYLENOL W/ CODEINE

/AA/	/MCNEIL/LABS/	/325MG;7.5MG/		/N85056/001/
/AA/		/325MG;15MG/		/N85056/002/
/AA/		/325MG;30MG/		/N85056/003/
/AA/		/325MG;60MG/		/N85056/004/
AA	MCNEIL PHARM	325MG;7.5MG		N85056 001
AA		325MG;15MG		N85056 002
AA		325MG;30MG		N85056 003
AA		325MG;60MG		N85056 004

TYLENOL W/ CODEINE NO. 1

/AA/	/MCNEIL/LABS/	/300MG;7.5MG/		/N85055/001/
AA	MCNEIL PHARM	300MG;7.5MG		N85055 001

TYLENOL W/ CODEINE NO. 2

/AA/	/MCNEIL/LABS/	/300MG;15MG/		/N85055/002/
AA	MCNEIL PHARM	300MG;15MG		N85055 002

TYLENOL W/ CODEINE NO. 3

/AA/	/MCNEIL/LABS/	/300MG;30MG/		/N85055/003/
AA	MCNEIL PHARM	300MG;30MG		N85055 003

TYLENOL W/ CODEINE NO. 4

/AA/	/MCNEIL/LABS/	/300MG;60MG/		/N85055/004/
AA	MCNEIL PHARM	300MG;60MG		N85055 004

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

AA	GRAHAM LABS	500MG;5MG		N87336 001 JUL 08, 1982

CO-GESIC

AA	CENTRAL PHARMS	500MG;5MG		N89360 001 MAR 02, 1988

/LORCET-HD/

/AA/	/GRAHAM/LABS/	/500MG;5MG/		/N87336/001/ /JUL/08,/1982/

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	BEECHAM LABS	650MG;7.5MG		N89725 001 SEP 30, 1987
AA	CHARLOTTE PHARM	500MG;5MG		N89831 001 SEP 07, 1988
AA	LUCHEM PHARMS	500MG;5MG		N89696 001 APR 21, 1988
AA	MIKART	650MG;7.5MG		N89689 001 JUN 29, 1988

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	HALSEY DRUG	325MG;50MG	N72105 001 MAY 13, 1988
AB		650MG;100MG	N72106 001 MAY 13, 1988
AB	MYLAN PHARMS	650MG;100MG	N72195 001 FEB 16, 1988

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

AB	MUTUAL PHARM	125MG	N89752 001 JUN 22, 1988
AB		250MG	N89753 001 JUN 22, 1988

DIAMOX

AB	LEDERLE LABS	125MG	N08943 001

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

AP	QUAD PHARMS	500MG/VIAL	N89619 001 JAN 13, 1988

DIAMOX

AP	LEDERLE LABS	500MG/VIAL	N09388 001

ACETOHYDROXAMIC ACID

TABLET; ORAL
LITHOSTAT

	MISSION PHARMA	250MG	N18749 001 MAY 31, 1983
	/URO/RES/	/250MG/	/N18749/001/ /MAY/31./1983/

ALBUTEROL SULFATE

CAPSULE; INHALATION
VENTOLIN ROTACAPS

	GLAXO	EQ 0.2MG BASE	N19489 001 MAY 04, 1988

ALSEROXYLON

TABLET; ORAL
/RAUTENSIN/

/BP/	/DORSEY/LABS/	/2MG/	/N09215/001/
	ə DORSEY LABS	2MG	N09215 001

/RAUNILOID/

/BP/	/RIKER LABS/	/2MG/	/N08867/001/
	RAUNILOID		
	RIKER LABS	2MG	N08867 001

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
/AMANTADINE HCL/

/AB/	/REID/ROWELL	/100MG/	/N71000/001/ /SEP/04./1986/

SYMADINE

AB	REID ROWELL	100MG	N71000 001 SEP 04, 1986

AMCINONIDE

LOTION; TOPICAL
CYCLOCORT

	LEDERLE LABS	0.1%	N19729 001 JUN 13, 1988

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

AB	BARR LABS	5MG;50MG	N71111 001 MAY 10, 1988

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN 3.5% IN PLASTIC CONTAINER

/ABBOTT/LABS/	/3.5%/	/N18875/001/ /AUG/08./1984/
ə ABBOTT LABS	3.5%	N18875 001 AUG 08, 1984

/NEOPHAN/6.4%/

/KABIVITRUM/	/6.4%/	/N18792/001/ /JAN/17./1984/
ə KABIVITRUM	6.4%	N18792 001 JAN 17, 1984

TRAVASOL 10% IN PLASTIC CONTAINER

BAXTER	10%	N18931 004 APR 27, 1988

AMINO ACIDS

INJECTABLE; INJECTION
TROPHAMINE 10%
KENDALL MCGAW 10%Ⓡ N19018 003
SEP 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ADD ADD ADD ADD ABBOTT LABS 3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100MLⓇ N19683 001
NOV 07, 1988
3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100MLⓇ N19714 001
SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
ADD ADD ADD ADD ABBOTT LABS 4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100MLⓇ N19683 002
NOV 07, 1988
4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100MLⓇ N19714 002
SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
AOD ADD ADD ADD ABBOTT LABS 4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100MLⓇ N19683 003
NOV 07, 1988
4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100MLⓇ N19714 004
SEP 12, 1988

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ADD ADD ADD ADD ABBOTT LABS 5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100MLⓇ N19683 004
NOV 07, 1988
5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100MLⓇ N19714 003
SEP 12, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ADD ADD ABBOTT LABS 3.5%;25GM/100MLⓇ N19681 001
NOV 01, 1988
3.5%;25GM/100MLⓇ N19713 006
SEP 09, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
ADD ADD ABBOTT LABS 3.5%;5GM/100MLⓇ N19681 002
NOV 01, 1988
3.5%;5GM/100MLⓇ N19713 002
SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
ADD ADD ABBOTT LABS 4.25%;10GM/100MLⓇ N19681 004
NOV 01, 1988
4.25%;10GM/100MLⓇ N19713 001
SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
ADD ADD ABBOTT LABS 4.25%;20GM/100MLⓇ N19681 005
NOV 01, 1988
4.25%;20GM/100MLⓇ N19713 004
SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
ADD ADD ABBOTT LABS 4.25%;25GM/100MLⓇ N19681 003
NOV 01, 1988
4.25%;25GM/100MLⓇ N19713 005
SEP 09, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ADD ADD ABBOTT LABS 5%;25GM/100MLⓇ N19681 006
NOV 01, 1988
5%;25GM/100MLⓇ N19713 003
SEP 09, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
ADD ADD ADD ADD ADD ABBOTT LABS 4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML; 205MG/100MLⓇ N19682 003
NOV 01, 1988
4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML; 205MG/100MLⓇ N19712 002
SEP 08, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

>ADD>	ABBOTT LABS	3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML‡	N19682 001	NOV 01, 1988
>ADD>		3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML‡	N19712 001	SEP 08, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

>ADD>	ABBOTT LABS	4.25%;10GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML‡	N19682 002	NOV 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

	KENDALL MCGAW	8.5%;110MG/100ML;230MG/100ML; 10MG/100ML;440MG/100ML; 690MG/100ML‡	N16822 007	JUL 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

/AMINOSYN/3.5%/M/IN/PLASTIC/CONTAINER/

	/ABBOTT/LABS/	/3.5%;21MG/100ML;40MG/100ML; 128MG/100ML;/ 234MG/100ML/	/N18875/002/	/AUG/08,/1984/
	ə ABBOTT LABS	3.5%;21MG/100ML;40MG/100ML; 128MG/100ML; 234MG/100ML	N18875 002	AUG 08, 1984

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP	ABBOTT LABS	250MG/ML‡	N70888 001	JUN 16, 1988

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

AP	MS&D	20%‡	N05619 001	
AP	QUAD PHARMS	20%‡	N89821 001	JUL 14, 1988

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

/BD/	/BARR/LABS/	/100MG/	/N88297/001/	/AUG/19,/1983/
/BD/		/200MG/	/N88298/001/	/AUG/19,/1983/
	ə BARR LABS	100MG	N88297 001	AUG 19, 1983
	ə	200MG	N88298 001	AUG 19, 1983
BD	HALSEY DRUG	100MG	N84674 001	
	/ə/	/100MG/	/N84674/001/	
>ADD> BD	RICHLYN LABS	100MG	N84574 001	
>ADD> BD		200MG	N84576 001	
>DLT>	/ə/	/100MG/	/N84574/001/	
>DLT>	/ə/	/200MG/	/N84576/001/	
BD	VALE CHEM	100MG	N84533 001	
	/ə/	/100MG/	/N84533/001/	

AMINOSALICYLATE SODIUM

TABLET; ORAL

/TEEBACIN/

/BP/	/CNSOL/MIDLAND/	/500MG/	/N07320/002/	
	ə CNSOL MIDLAND	500MG	N07320 002	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIL

/AB/	/PARKE/DAVIS/	/10MG/	/N83936/001/	
/AB/		/25MG/	/N83937/001/	
/AB/		/50MG/	/N83938/002/	
/AB/		/75MG/	/N84957/001/	
/AB/		/100MG/	/N85093/001/	
/AB/		/150MG/	/N86295/001/	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIL

AB	MARNER CHILCOTT	10MG	N83939 001
AB		25MG	N83937 001
AB		50MG	N83938 002
AB		75MG	N84957 001
AB		100MG	N85093 001
AB		150MG	N86295 001

AMITRIPTYLINE HCL

/AB/	/LEDERLE LABS/	/10MG/	[illegible]
/AB/		/25MG/	
/AB/		/50MG/	
/AB/		/75MG/	
/AB/		/100MG/	
∂	LEDERLE LABS	10MG	[illegible]
∂		25MG	N86746 001
∂		50MG	N86743 001
∂		75MG	N86745 001
∂		100MG	N86747 001

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

AB	PAR PHARM	EQ 12.5MG BASE;5MG‡	N72277 001 MAY 09, 1988
AB		25MG;10MG‡	N72278 001 MAY 09, 1988
AB	PHARM BASICS	EQ 12.5MG BASE;5MG‡	N70477 001 JAN 12, 1988
AB		EQ 25MG BASE;10MG‡	N70478 001 JAN 12, 1988

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

>ADD>	AB	MYLAN PHARMS	10MG;2MG‡	N70336 001 NOV 10, 1988
>ADD>	AB		10MG;4MG‡	N71442 001 NOV 10, 1988
>ADD>	AB		25MG;2MG‡	N70337 001 NOV 10, 1988
>ADD>	AB		25MG;4MG‡	N70338 001 NOV 10, 1988
>ADD>	AB		50MG;4MG‡	N71443 001 NOV 10, 1988

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	CLONMEL CHEMS	250MG‡	N62884 001 FEB 25, 1988
AB		500MG‡	N62881 001 FEB 25, 1988

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

>ADD> AB	CLONMEL CHEMS	125MG/5ML‡	N62927 001 NOV 25, 1988
>ADD> AB		250MG/5ML‡	N62927 002 NOV 25, 1988
>ADD> AB	NOVOPHARM	125MG/5ML‡	N62946 001 NOV 01, 1988

POLYMOX

AB	BRSTL MYRS IND	125MG/5ML‡	N62885 001 MAR 08, 1988
AB		250MG/5ML‡	N62885 002 MAR 08, 1988

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	MARSAM PHARMS	EQ 125MG BASE/VIAL‡	N62816 001 OCT 24, 1988
AP		EQ 250MG BASE/VIAL‡	N62816 002 OCT 24, 1988
AP		EQ 500MG BASE/VIAL‡	N62816 003 OCT 24, 1988
AP		EQ 1GM BASE/VIAL‡	N62816 004 OCT 24, 1988
AP		EQ 2GM BASE/VIAL‡	N62816 005 OCT 24, 1988
AP		EQ 10GM BASE/VIAL‡	N62994 001 SEP 15, 1988

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

>ADD>	PFIZER LABS	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL‡	N62901 001 NOV 23, 1988

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	AMPICILLIN			
AB	CLONMEL CHEMS	EQ 250MG BASE*	N62883 001	FEB 25, 1988
AB		EQ 500MG BASE*	N62882 001	FEB 25, 1988
/AA/	/LEDERLE LABS/	/EQ 250MG BASE/	/N62208 001/	
/AA/		/EQ 500MG BASE/	/N62208 002/	
	∂ LEDERLE LABS	EQ 250MG BASE	N62208 001	
	∂	EQ 500MG BASE	N62208 002	
	POLYCILLIN			
AB	BRSTL MYRS IND	EQ 250MG BASE*	N62888 001	MAR 04, 1988
AB		EQ 500MG BASE*	N62888 002	MAR 04, 1988

POWDER FOR RECONSTITUTION; ORAL

	/PENICILLIN/			
/AA/	/AYERST LABS/	/EQ 125MG BASE/5ML/	/N50019 002/	
/AA/		/EQ 250MG BASE/5ML/	/N50019 003/	
/AA/		/EQ 100MG BASE/ML/	/N50019 001/	
	∂ AYERST LABS	EQ 125MG BASE/5ML	N50019 002	
	∂	EQ 250MG BASE/5ML	N50019 003	
	∂	EQ 100MG BASE/ML	N50019 001	

ANILERIDINE HYDROCHLORIDE

	/TABLET; ORAL/			
	/LERITINE/			
	/MS&D/	/EQ 25MG BASE/	/N10585 002/	
	∂ MS&D	EQ 25MG BASE	N10585 002	

ANILERIDINE PHOSPHATE

	/INJECTABLE; INJECTION/			
	/LERITINE/			
	/MS&D/	/EQ 25MG BASE/ML/	/N10520 003/	
	∂ MS&D	EQ 25MG BASE/ML	N10520 003	

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

	ORPHENADRINE COMPOUND			
AB	VITARINE	385MG;30MG;25MG*	N71564 001	JUN 23, 1988
	ORPHENADRINE COMPOUND DOUBLE STRENGTH			
AB	VITARINE	770MG;60MG;50MG*	N71565 001	JUN 23, 1988

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

/AA/	/BANMAX/PHARMS/	/389MG;32.4MG;65MG/	/N84553/002/	/AUG/17./1983/
	∂ BANMAX PHARMS	389MG;32.4MG;65MG	N84553 002	AUG 17, 1983

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

	AZDONE			
	CENTRAL PHARMS	500MG;5MG*	N89420 001	JAN 25, 1988

ASPIRIN; MEPROBAMATE

TABLET; ORAL

	MEPRO-ASPIRIN				
> ADD >	AB VITARINE	325MG;200MG	N89127 001		MAR 02, 1987
	/MEPROGESIC/				
> ADD >	/AA/ /VITARINE/	/325MG;200MG/	/N84127/001/		/MAR/02./1987/
> DLT >					
> DLT >					
> DLT >					

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL AND ASPIRIN			
> ADD >	AB PAR PHARM	325MG;400MG*	N89657 001	NOV 04, 1988
> ADD >				

ATENOLOL

TABLET; ORAL

	ATENOLOL			
AB	ICI PHARMS	50MG*	N72303 001	JUL 15, 1988
AB		100MG*	N72304 001	JUL 15, 1988
	TENORMIN			
AB	STUART PHARMS	50MG	N18240 001	
AB		100MG	N18240 002	

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

	MOTOFEN		
	CARNRICK LABS	0.025MG;1MG	N17744 002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

	AZATHIOPRINE		
AP	QUAD PHARMS	EQ 100MG BASE/VIAL*	N71056 001 JUN 08, 1988
	IMURAN		
AP	BURROUGHS WELLC	EQ 100MG BASE/VIAL*	N17391 001

BACLOFEN

TABLET; ORAL

	BACLOFEN		
AB	PHARM BASICS	10MG*	N71260 001 MAY 06, 1988
AB		20MG*	N71261 001 MAY 06, 1988
AB	VITARINE	10MG*	N71901 001 APR 13, 1988
AB		20MG*	N71902 001 APR 13, 1988
AB	ZENITH LABS	10MG*	N72234 001 JUL 21, 1988
AB		20MG*	N72235 001 JUL 21, 1988
	LIORESAL		
AB	GEIGY PHARMS	10MG*	N17851 001
	LIORESAL DS		
AB	GEIGY PHARMS	20MG*	N17851 003 JAN 20, 1982

BENZTHIAZIDE

TABLET; ORAL

	BENZTHIAZIDE		
∂	PRIVATE FMLTNS	50MG	N83206 001

BENZTROPINE MESYLATE

TABLET; ORAL

	BENZTROPINE MESYLATE		
AA	PAR PHARM	0.5MG	N88877 001 APR 11, 1985
AA		1MG	N88894 001 APR 11, 1985
AA		2MG	N88895 001 APR 11, 1985
AA	PHARM BASICS	0.5MG*	N89211 001 JUN 14, 1988
AA		1MG*	N89212 001 JUN 14, 1988
AA		2MG*	N89213 001 JUN 14, 1988
AA	QUANTUM PHARMCS	0.5MG	N88514 001 JAN 31, 1984
AA		1MG	N88510 001 JAN 31, 1984
AA		2MG	N88511 001 JAN 31, 1984
AA	SIDMAK LABS	0.5MG*	N89058 001 AUG 10, 1988
AA		1MG*	N89059 001 AUG 10, 1988
AA		2MG*	N89060 001 AUG 10, 1988
	COGENTIN		
AA	MSD	0.5MG	N09193 004
AA		1MG	N09193 003
AA		2MG	N09193 002

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	COPLEY PHARM	EQ 0.05% BASE‡	N71882 001 JUN 06, 1988
AB	THAMES PHARMA	EQ 0.05% BASE‡	N72276 001 AUG 24, 1988

DIPROLENE

BX	SCHERING	EQ 0.05% BASE‡	N19716 001 AUG 01, 1988

BETAMETHASONE VALERATE

CREAM; TOPICAL
DERMABET

AB	TARO PHARMS	EQ 0.1% BASE‡	N72041 001 JAN 06, 1988

LOTION; TOPICAL
BETAMETHASONE VALERATE

AB	COPLEY PHARM	EQ 0.1% BASE‡	N71883 001 APR 22, 1988

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
/HISTALOG/
/LILLY/ /50MG/ML/ /N09344/001/
a LILLY 50MG/ML N09344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION
BETHANECHOL CHLORIDE

AP	QUAD PHARMS	5MG/ML‡	N89815 001 APR 12, 1988

URECHOLINE

AP	MSD	5MG/ML	N06536 001

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

AP	LUITPOLD PHARMS	50MG/ML‡	N70891 001 JUL 26, 1988
AP	QUAD PHARMS	50MG/ML‡	N71181 001 FEB 16, 1988

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE

/AA/	/BARR/LABS/	/4MG/	/N84468/001/
a	BARR LABS	4MG	N84468 001

BUPIVACAINE HYDROCHLORIDE; DEXTROSE

> DLT > /INJECTABLE;INJECTION/
> DLT > /MARCAINE/SPINAL/
> DLT > /S/STERLING/DRUG/ /0.75%;8.25%/ /N18692/001/
> DLT > /MAY/04/1984/
> ADD > INJECTABLE; INJECTION
> ADD > MARCAINE SPINAL
> ADD > NINTHROP PHARM 0.75%;8.25% N18692 001
> ADD > MAY 04, 1984

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION
BUPIVACAINE HCL AND EPINEPHRINE

ABBOTT LABS	0.25%;0.005MG/ML‡	N71165 001 JUN 16, 1988
	0.25%;0.005MG/ML‡	N71166 001 JUN 16, 1988
	0.25%;0.005MG/ML‡	N71167 001 JUN 16, 1988
	0.5%;0.005MG/ML‡	N71168 001 JUN 16, 1988
	0.5%;0.005MG/ML‡	N71169 001 JUN 16, 1988
	0.5%;0.005MG/ML‡	N71170 001 JUN 16, 1988
	0.75%;0.005MG/ML‡	N71171 001 JUN 16, 1988

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	BAXTER	25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML‡	N17512 010 NOV 18, 1985

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	BAXTER	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML‡	N17512 011 NOV 18, 1985

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	ABBOTT LABS	25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML‡	N18379 007 JUN 24, 1988

INPERSOL-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	ABBOTT LABS	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML‡	N18379 008 JUN 24, 1988

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	KENDALL MCGAW	10MG/100ML;2.5GM/100ML;15MG/100ML; 300MG/100ML; 160MG/100ML‡	N19634 001 FEB 24, 1988

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

	KENDALL MCGAW	4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML‡	N19634 002 FEB 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	KENDALL MCGAW	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML; 310MG/100ML‡	N19634 003 FEB 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML; 310MG/100ML‡	N19685 005 OCT 17, 1988
AP		20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML; 310MG/100ML‡	N19685 006 OCT 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML; 310MG/100ML‡	N19685 007 OCT 17, 1988

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML; 310MG/100ML‡	N19685 002 OCT 17, 1988
AP		20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML; 310MG/100ML‡	N19685 008 OCT 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML; 310MG/100ML‡	N19685 003 OCT 17, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGERS'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML; 310MG/100ML‡	N19685 004 OCT 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML; 310MG/100ML‡	N19685 001 OCT 17, 1988

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	KENDALL MCGAW	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML‡	N19632 001 FEB 29, 1988

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB	WARNER CHILCOTT	100MG‡	N71940 001 FEB 01, 1988

TEGRETOL

AB	GEIGY PHARMS	100MG	N18281 001

CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL			
AA	PIONEER PHARMS	350MG[M]	N89390 001	OCT 13, 1988
AA	VITARINE	350MG[M]	N89566 001	AUG 30, 1988

CARPHENAZINE MALEATE

	/TABLET;ORAL/			
	/PROMAZINE/			
	/WYETH/AYERST/LABS/	/25MG/	/N12768/002/	
	ə WYETH AYERST LABS	25MG	N12768 002	
	/50MG/		/N12768/004/	
	ə	50MG	N12768 004	

CARPROFEN

>_DLT_>	/TABLET;ORAL/			
>_DLT_>	/RIMADYL/			
>_DLT_>	/ROCHE/	/100MG/	/N18550/002/	
>_DLT_>			/DEC/31,/1987/	
>_ADD_>	ə ROCHE	100MG	N18550 002	DEC 31, 1987
>_ADD_>				
>_DLT_>		/150MG/	/N18550/003/	
>_DLT_>			/DEC/31,/1987/	
>_ADD_>	ə	150MG	N18550 003	DEC 31, 1987
>_ADD_>				

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

	CECLOR			
	LILLY	EQ 187MG BASE/5ML[M]	N62206 003	APR 20, 1988
		EQ 375MG BASE/5ML[M]	N62206 004	APR 20, 1988

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	ANDEF			
AP	SK&F LABS	EQ 5GM BASE/VIAL	N50461 004	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM			
AP	BEN VENUE LABS	EQ 250MG BASE/VIAL[M]	N62894 001	JUL 21, 1988
AP		EQ 500MG BASE/VIAL[M]	N62894 002	JUL 21, 1988
AP		EQ 1GM BASE/VIAL[M]	N62894 003	JUL 21, 1988
AP		EQ 5GM BASE/VIAL[M]	N62894 004	JUL 21, 1988
AP		EQ 10GM BASE/VIAL[M]	N62894 005	JUL 21, 1988
AP	ELKINS SINN	EQ 250MG BASE/VIAL[M]	N62807 001	JAN 12, 1988
AP		EQ 500MG BASE/VIAL[M]	N62807 002	JAN 12, 1988
AP		EQ 1GM BASE/VIAL[M]	N62807 003	JAN 12, 1988
AP		EQ 5GM BASE/VIAL[M]	N62807 004	JAN 12, 1988
AP		EQ 10GM BASE/VIAL[M]	N62807 005	JAN 12, 1988
AP		EQ 20GM BASE/VIAL[M]	N62807 006	JAN 12, 1988

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

	CEFOTAN			
	STUART PHARMS	EQ 10GM BASE/VIAL[M]	N50588 003	APR 25, 1988

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	JEROME STEVENS	EQ 250MG BASE[M]	N62870 001	MAR 17, 1988
AB		EQ 500MG BASE[M]	N62869 001	MAR 17, 1988
AB	LABROS ATRAL	EQ 250MG BASE[M]	N62713 001	JUL 15, 1988
AB		EQ 500MG BASE[M]	N62713 002	JUL 15, 1988
>_ADD_> AB	SQUIBB MARK	EQ 250MG BASE[M]	N62973 001	NOV 08, 1988
>_ADD_>				
>_ADD_> AB		EQ 500MG BASE[M]	N62974 001	NOV 23, 1988
>_ADD_>				

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB	TAG PHARMS	EQ 250MG BASE	N62821 001 FEB 05, 1988
AB		EQ 500MG BASE	N62823 001 FEB 05, 1988
AB	YOSHITOMI PHARM	EQ 250MG BASE	N62872 001 JUN 20, 1988
AB		EQ 500MG BASE	N62871 001 JUL 05, 1988

POWDER FOR RECONSTITUTION; ORAL

CEPHALEXIN

AB	TAG PHARMS	EQ 125MG BASE/5ML	N62873 001 MAY 23, 1988
AB		EQ 250MG BASE/5ML	N62867 001 APR 15, 1988

TABLET; ORAL

CEPHALEXIN

AB	VITARINE	EQ 250MG BASE	N62863 001 AUG 11, 1988
AB		EQ 500MG BASE	N62863 002 AUG 11, 1988
AB		EQ 1GM BASE	N62863 003 AUG 11, 1988

KEFLET

AB	LILLY	EQ 1GM BASE	N50440 002

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

	LILLY	EQ 333MG BASE	N50614 003 MAY 16, 1988

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

AP	BRSTL MYRS IND	EQ 500MG BASE/VIAL	N62961 001 SEP 20, 1988
AP		EQ 1GM BASE/VIAL	N62961 002 SEP 20, 1988
AP		EQ 2GM BASE/VIAL	N62961 003 SEP 20, 1988
AP		EQ 4GM BASE/VIAL	N62961 004 SEP 20, 1988

CEPHRADINE

CAPSULE; ORAL

CEPHRADINE

AB	BARR LABS	250MG	N62850 001 APR 22, 1988
AB		500MG	N62851 001 APR 22, 1988
AB	VITARINE	250MG	N62813 001 FEB 25, 1988
AB		500MG	N62813 002 FEB 25, 1988

POWDER FOR RECONSTITUTION; ORAL

CEPHRADINE

AB	BARR LABS	125MG/5ML	N62858 001 MAY 19, 1988
AB		250MG/5ML	N62859 001 MAY 19, 1988

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

/AB/	/LEDERLE LABS/	/5MG/	/N86892/001/
/AB/		/10MG/	/N86876/001/
/AB/		/25MG/	/N86893/001/
ə	LEDERLE LABS	5MG	N86892 001
ə		10MG	N86876 001
ə		25MG	N86893 001
AB	PIONEER PHARMS	10MG	N89533 001 JUL 15, 1988
AB		25MG	N89558 001 JUL 15, 1988
/AB/	/PUREPAC PHARM/	/5MG/	/N85155/001/
/AB/		/10MG/	/N84939/002/
/AB/		/25MG/	/N85144/001/
ə	PUREPAC PHARM	5MG	N85155 001
ə		10MG	N84939 002
ə		25MG	N85144 001
	/LYDEN/		
/AB/	/BANMAX PHARMS/	/5MG/	/N85107/002/
/AB/		/10MG/	/N85009/001/
/AB/		/25MG/	/N85108/001/
ə	BANMAX PHARMS	5MG	N85107 002
ə		10MG	N85009 001
ə		25MG	N85108 001

CHLORMERODRIN, HG-197

	INJECTABLE; INJECTION		
	CHLORMERODRIN, HG-197		
	SQUIBB	0.6-1.4MCI/ML	N17269 001
	∂ SQUIBB	0.6-1.4MCI/ML	N17269 001

CHLOROQUINE HYDROCHLORIDE

	INJECTABLE; INJECTION		
	ARALEN		
	STERLING DRUG	EQ 40MG BASE/ML	N06002 002
	∂ STERLING DRUG	EQ 40MG BASE/ML	N06002 002

CHLOROQUINE PHOSPHATE

	TABLET; ORAL		
	ARALEN		
AA	STERLING DRUG	EQ 300MG BASE*	N06002 001
	CHLOROQUINE PHOSPHATE		
AA	DANBURY PHARMA	EQ 300MG BASE	N88030 001 DEC 21, 1982
AA		EQ 300MG BASE	N88030 001 DEC 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

	TABLET; ORAL		
	ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE		
	STERLING DRUG	EQ 300MG BASE; EQ 45MG BASE	N14860 002
	∂ STERLING DRUG	EQ 300MG BASE; EQ 45MG BASE	N14860 002

CHLOROTHIAZIDE

	TABLET; ORAL		
	CHLOROTHIAZIDE		
AA	LEDERLE LABS	250MG	N86940 001
AA		500MG	N86938 001
	∂ LEDERLE LABS	250MG	N86940 001
	∂	500MG	N86938 001

CHLOROTHIAZIDE; RESERPINE

	TABLET; ORAL		
	CHLOROTHIAZIDE W/ RESERPINE		
BP	BOLAR PHARM	250MG;0.125MG	N84853 001
	∂ BOLAR PHARM	250MG;0.125MG	N84853 001

CHLORPHENIRAMINE MALEATE

	TABLET; ORAL		
	CHLORPHENIRAMINE MALEATE		
AA	BARR LABS	4MG	N80700 001
	∂ BARR LABS	4MG	N80700 001

CHLORPROMAZINE HYDROCHLORIDE

	INJECTABLE; INJECTION		
	CHLORPROMAZINE HCL		
AP	MARSAM PHARMS	25MG/ML*	N89563 001 APR 15, 1988
	TABLET; ORAL		
	CHLORPROMAZINE HCL		
BP	LEDERLE LABS	25MG	N84801 001
BP		50MG	N84800 001
BP		200MG	N84802 001
	∂ LEDERLE LABS	25MG	N84801 001
	∂	50MG	N84800 001
	∂	200MG	N84802 001

CHLORTHALIDONE

	TABLET; ORAL		
	CHLORTHALIDONE		
AB	MUTUAL PHARM	25MG*	N89738 001 SEP 19, 1988
AB		50MG*	N89739 001 SEP 19, 1988
AB	PIONEER PHARMS	50MG*	N89591 001 JUL 21, 1988

CHLORZOXAZONE

	TABLET; ORAL		
	CHLORZOXAZONE		
AA	BARR LABS	500MG*	N89895 001 MAY 04, 1988

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	CORD LABS	250MG	N89852 001 MAY 04, 1988
AA		500MG	N89853 001 MAY 04, 1988
AA	LEMMON	500MG	N89859 001 MAY 04, 1988

PARAFON FORTE DSC

AA	MCNEIL PHARM	500MG	N11529 002 JUN 15, 1987

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

	PARKE DAVIS	EQ 4GM RESIN/BAR	N71621 001 MAY 26, 1988
		EQ 4GM RESIN/BAR	N71739 001 MAY 26, 1988

CISPLATIN

INJECTABLE; INJECTION

>ADD>	PLATINOL-AQ		
>ADD>	BRISTOL MYERS	1MG/ML	N18057 004 NOV 08, 1988
>ADD>			

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

AB	UPJOHN MFG	EQ 75MG BASE	N61809 001
AB		EQ 150MG BASE	N61809 002

CLEOCIN HCL

	UPJOHN	EQ 300MG BASE	N50162 003 APR 14, 1988

CLINDAMYCIN HCL

AB	VITARINE	EQ 75MG BASE	N62910 001 JUL 05, 1988
AB		EQ 150MG BASE	N62910 002 JUL 05, 1988

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	ABBOTT LABS	EQ 150MG BASE/ML	N62943 001 SEP 29, 1988
AP	ELKINS SINN	EQ 150MG BASE/ML	N62953 001 APR 21, 1988
AP	LEDERLE PARNTLS	EQ 150MG BASE/ML	N62889 001 APR 25, 1988
AP	LEMMON	EQ 150MG BASE/ML	N62900 001 JUN 08, 1988
AP	LOCH PHARMS	EQ 150MG BASE/ML	N62905 001 MAY 09, 1988
AP	LYPHOMED	EQ 150MG BASE/ML	N62747 001 JUN 03, 1988
AP	MARSAM PHARMS	EQ 150MG BASE/ML	N62913 001 OCT 20, 1988
AP	QUAD PHARMS	EQ 150MG BASE/ML	N62877 001 MAR 15, 1988
AP	SOLOPAK LABS	EQ 150MG BASE/ML	N62819 001 MAR 15, 1988
AP		EQ 150MG BASE/ML	N62852 001 MAR 17, 1988

SOLUTION; TOPICAL

CLEOCIN T

AT	UPJOHN	EQ 1% BASE	N50537 001
AT		EQ 1% BASE	N62363 001 FEB 08, 1982

CLINDAMYCIN PHOSPHATE

AT	BARRE NATL	EQ 1% BASE	N62811 001 SEP 01, 1988

CLOFIBRATE

CAPSULE; ORAL

CLOFIBRATE

AB	CORD LABS	500MG	N72191 001 MAY 02, 1988

CLOMIPHENE CITRATE

TABLET; ORAL

~~CLOMIPHENE CITRATE~~

/AB/	/PLANTEX/	/50MG/	/N18361/001/ MAR/22/1982/

SEROPHENE

AB	SERONO LABS	50MG	N18361 001 MAR 22, 1982

CLONIDINE

FILM, CONTROLLED RELEASE; PERCUTANEOUS

CATAPRES-TTS-1			
BOEHR INGEL	0.1MG/24HR	N18891 001	
	/2.5MG/	OCT 10, 1984 /N18891/001/ /OCT/10/1984/	
CATAPRES-TTS-2			
BOEHR INGEL	0.2MG/24HR	N18891 002	
	/5MG/	OCT 10, 1984 /N18891/002/ /OCT/10/1984/	
CATAPRES-TTS-3			
BOEHR INGEL	0.3MG/24HR	N18891 003	
	/7.5MG/	OCT 10, 1984 /N18891/003/ /OCT/10/1984/	

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HCL			
AB	CORD LABS	0.1MG	N70887 001 AUG 31, 1988
AB		0.2MG	N70886 001 AUG 31, 1988
AB		0.3MG	N71294 001 AUG 31, 1988
AB	LEDERLE LABS	0.1MG	N71783 001 APR 05, 1988
AB		0.2MG	N71784 001 APR 05, 1988
AB		0.3MG	N71785 001 APR 05, 1988
AB	MARNER CHILCOTT	0.1MG	N72138 001 JUN 13, 1988
AB		0.2MG	N72139 001 JUN 13, 1988
AB		0.3MG	N72140 001 JUN 13, 1988

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM			
AB	CHELSEA LABS	3.75MG	N71878 001 MAR 15, 1988
AB		7.5MG	N71879 001 MAR 15, 1988
AB		15MG	N71860 001 MAR 15, 1988
AB	CORD LABS	3.75MG	N72219 001 AUG 26, 1988
AB		7.5MG	N72220 001 AUG 26, 1988
AB		15MG	N72112 001 AUG 26, 1988
AB	PUREPAC PHARM	3.75MG	N71924 001 APR 25, 1988
AB		7.5MG	N71925 001 APR 25, 1988
AB		15MG	N71926 001 APR 25, 1988
AB	QUANTUM PHARMCS	3.75MG	N71549 001 SEP 12, 1988
AB		7.5MG	N71550 001 SEP 12, 1988
AB		15MG	N71522 001 SEP 12, 1988
AB	MARNER CHILCOTT	3.75MG	N71774 001 MAR 01, 1988
AB		7.5MG	N71775 001 MAR 01, 1988
AB		15MG	N71776 001 MAR 01, 1988

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM			
AB	PUREPAC PHARM	3.75MG	N72330 001 AUG 08, 1988
AB		7.5MG	N72331 001 AUG 08, 1988
AB		15MG	N72332 001 AUG 08, 1988
AB	MARNER CHILCOTT	3.75MG	N71828 001 MAR 03, 1988
AB		7.5MG	N71829 001 MAR 03, 1988
AB		15MG	N71830 001 MAR 03, 1988

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

AP	NATSON LABS	3.75MG*	N71852 001	>ADD>	
			FEB 09, 1988	>DLT>	
AB		7.5MG*	N71853 001		
			FEB 09, 1988		
AB		15MG*	N71854 001		
			FEB 09, 1988		

GEN-XENE

AB	ALRA LABS	3.75MG*	N71787 001
			APR 26, 1988
AB		7.5MG*	N71788 001
			APR 26, 1988
AB		15MG*	N71789 001
			APR 26, 1988

CLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL

CLOXACILLIN SODIUM

AA	BIOCRAFT LABS	EQ 125MG BASE/5ML	N62268 001

TEDOPEN

AA	BRISTOL LABS	EQ 125MG BASE/5ML	N50192 001
AA		EQ 125MG BASE/5ML	N61453 001

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

	∂ BEECHAM LABS	0.5MG;500MG	N84321 001

PROBENECID W/ COLCHICINE

	∂ LEDERLE LABS	0.5MG;500MG	N86954 001

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

INTRAUTERINE COPPER CONTRACEPTIVE

	POP COUNCIL CBR	APPROX 176MG COPPER*	N18680 002
			APR 29, 1988

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

BP	RICHLYN LABS	25MG	N09458 001		

CYCLACILLIN

TABLET; ORAL

CYCLACILLIN

AB	BIOCRAFT LABS	250MG*	N62895 001
			AUG 04, 1988
AB		500MG*	N62895 002
			AUG 04, 1988

CYCLAPEN-N

AB	WYETH AYERST LABS	250MG	N50509 001
AB		500MG	N50509 002

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HCL

AB	DANBURY PHARMA	10MG*	N71611 001
			MAY 03, 1989 : FEB 29, 1988

FLEXERIL

AB	MSD	10MG	N17821 002

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL

PAGITANE

	∂ LILLY	1.25MG	N08951 001
	∂	2.5MG	N08951 002

CYTARABINE

INJECTABLE; INJECTION

CYTOSAR-U

	UPJOHN	1GM/VIAL	N16793 003
			DEC 21, 1987
		2GM/VIAL	N16793 004
			DEC 21, 1987

DACARBAZINE

INJECTABLE; INJECTION
DACARBAZINE
QUAD PHARMS 500MG/VIAL(M) N71563 001 MAY 06, 1988

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB CORD LABS 10MG(M) N72099 001 MAY 24, 1988
AB 25MG(M) N72100 001 MAY 24, 1988
AB 50MG(M) N72101 001 MAY 24, 1988
AB 75MG(M) N72102 001 JUN 20, 1988
AB 100MG(M) N72103 001 JUN 20, 1988
AB 150MG(M) N72104 001 JUN 20, 1988
AB VITARINE 10MG(M) N72167 001 FEB 03, 1988
AB 150MG(M) N72254 001 FEB 03, 1988

NORPRAMIN
AB HERRELL DON 10MG N14399 007 FEB 11, 1982
AB 150MG N14399 006

DESONIDE

OINTMENT; TOPICAL
DESOWEN
AB OWEN LABS 0.05%(M) N71425 001 JUN 15, 1988

TRIDESILON
AB MILES PHARM 0.05% N17426 001

DESOXYCORTICOSTERONE ACETATE

PELLET; IMPLANTATION
/PERCORTEN/
/CIBA/PHARM/ /125MG/ /N05151/001/
CIBA PHARM 125MG N05151 001

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE
/BP/ /BARR/LABS/ /0.25MG/
/BP/ /0.25MG/
/BP/ /0.5MG/
/BP/ /0.75MG/
/BP/ /0.75MG/
/BP/ /1.5MG/
/BP/ /1.5MG/
BARR LABS 0.25MG
0.25MG N84764 001
0.5MG N84084 001
0.75MG N84081 001
0.75MG N84765 001
1.5MG N84086 001
1.5MG N84763 001
>ADD> BP RICHLYN LABS 0.75MG N85376 001
>DLT> /3/ /0.75MG/ /N85376/001/

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC
TOBRADEX
ALCON LABS 0.1%;0.3%(M) N50616 001 SEP 28, 1988

SUSPENSION/DROPS; OPHTHALMIC
TOBRADEX
ALCON LABS 0.1%;0.3%(M) N50592 001 AUG 18, 1988

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
/PHENERGAN DM/DEXTROMETHORPHAN/
/AA/ /WYETH/AYERST/LABS/ /10MG/5ML;6.25MG/5ML/ /N11265/002/ APR 02, 1984

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 10% IN PLASTIC CONTAINER
AP KENDALL MCGAW 10GM/100ML(M) N19626 004 FEB 02, 1988

DEXTROSE 2.5% IN PLASTIC CONTAINER
KENDALL MCGAW 2.5GM/100ML(M) N19626 001 FEB 02, 1988

DEXTROSE

INJECTABLE; INJECTION

>DLT>	/DEXTROSE/38.5%/IN/PLASTIC/CONTAINER/			
>DLT>	/ABBOTT/LABS/	/38.5GM/100ML/	/N16923/001/	
>DLT>			/SEP/19/1984/	
>ADD>	3 ABBOTT LABS	38.5GM/100ML	N18923 001	
>ADD>			SEP 19, 1984	
	DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT LABS	50MG/ML	N19222 001	
			JUL 13, 1984	
	/3/	/50MG/ML/	/N19222/001/	
			/JUL/13/1984/	
AP	KENDALL MCGAW	5GM/100MLM	N19626 002	
			FEB 02, 1988	
	DEXTROSE 7.7% IN PLASTIC CONTAINER			
	KENDALL MCGAW	7.7GM/100MLM	N19626 003	
			FEB 02, 1988	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	/DEXTROSE/5%/AND/SODIUM/CHLORIDE/0.3%/N//POTASSIUM/CHLORIDE/			
	/0.075%/IN/PLASTIC/CONTAINER/			
	/ABBOTT/LABS/	/5GM/100ML;14.5MG/100ML;/		
		/300MG/100ML/	/N16876/001/	
			/JAN/17/1986/	
	/DEXTROSE/5%/AND/SODIUM/CHLORIDE/0.3%/N//POTASSIUM/CHLORIDE/			
	/0.15%/IN/PLASTIC/CONTAINER/			
	/ABBOTT/LABS/	/5GM/100ML;29MG/100ML;/		
		/300MG/100ML/	/N16876/002/	
			/JAN/17/1986/	
	/DEXTROSE/5%/AND/SODIUM/CHLORIDE/0.3%/N//POTASSIUM/CHLORIDE/			
	/0.225%/IN/PLASTIC/CONTAINER/			
	/ABBOTT/LABS/	/5GM/100ML;43.5MG/100ML;/		
		/300MG/100ML/	/N16876/003/	
			/JAN/17/1986/	
	/DEXTROSE/5%;/SODIUM/CHLORIDE/0.225%;/POTASSIUM/CHLORIDE/			
	/0.15%/IN/PLASTIC/CONTAINER/			
	/ABBOTT/LABS/	/5GM/100ML;15MG/100ML;/		
		/225MG/100ML/	/N16368/001/	
	/DEXTROSE 5%; SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE/			
	/0.225% IN PLASTIC CONTAINER/			
/AP/	/ABBOTT/LABS/	/5GM/100ML;22.5MG/100ML;/		
		/150MG/100ML/	/N16362/002/	
	/DEXTROSE 5%; SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE/			
	/0.3% IN PLASTIC CONTAINER/			
/AP/	/ABBOTT/LABS/	/5GM/100ML;30MG/100ML;/		
		/150MG/100ML/	/N16362/003/	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
KENDALL MCGAW	10GM/100ML;37MG/100ML; 200MG/100MLM	N19630 031 FEB 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
KENDALL MCGAW	10GM/100ML;37MG/100ML; 450MG/100MLM	N19630 037 FEB 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
KENDALL MCGAW	10GM/100ML;37MG/100ML; 900MG/100MLM	N19630 043 FEB 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		
KENDALL MCGAW	5GM/100ML;37MG/100ML; 110MG/100MLM	N19630 001 FEB 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
KENDALL MCGAW	5GM/100ML;37MG/100ML; 200MG/100MLM	N19630 007 FEB 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		
KENDALL MCGAW	5GM/100ML;37MG/100ML; 330MG/100MLM	N19630 013 FEB 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
KENDALL MCGAW	5GM/100ML;37MG/100ML; 450MG/100MLM	N19630 019 FEB 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
KENDALL MCGAW	5GM/100ML;37MG/100ML; 900MG/100MLM	N19630 025 FEB 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
KENDALL MCGAW	10GM/100ML;75MG/100ML; 200MG/100MLM	N19630 032 FEB 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
KENDALL MCGAW	10GM/100ML;75MG/100ML; 450MG/100MLM	N19630 038 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;75MG/100ML; 900MG/100MLM N19630 044 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;75MG/100ML; 200MG/100MLM N19630 008 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;75MG/100ML; 330MG/100MLM N19630 014 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;75MG/100ML; 450MG/100MLM N19630 020 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;75MG/100ML; 900MG/100MLM N19630 026 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;75MG/100ML; 110MG/100MLM N19630 002 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;110MG/100ML; 200MG/100MLM N19630 033 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;110MG/100ML; 450MG/100MLM N19630 039 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;110MG/100ML; 900MG/100MLM N19630 045 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 110MG/100MLM N19630 003 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 200MG/100MLM N19630 009 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 330MG/100MLM N19630 015 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 450MG/100MLM N19630 021 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;110MG/100ML; 900MG/100MLM N19630 027 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;150MG/100ML; 200MG/100MLM N19630 034 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;150MG/100ML; 450MG/100MLM N19630 040 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;150MG/100ML; 900MG/100MLM N19630 046 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;150MG/100ML; 200MG/100MLM N19630 010 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML;150MG/100ML; 330MG/100MLM N19630 016 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;150MG/100ML; 450MG/100MLM N19630 022 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;150MG/100ML; 900MG/100MLM N19630 028 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;150MG/100ML; 110MG/100MLM N19630 004 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;220MG/100ML; 200MG/100MLM N19630 035 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;220MG/100ML; 450MG/100MLM N19630 041 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;220MG/100ML; 900MG/100MLM N19630 047 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;220MG/100ML; 110MG/100MLM N19630 005 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;220MG/100ML; 200MG/100MLM N19630 011 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;220MG/100ML; 330MG/100MLM N19630 017 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;220MG/100ML; 450MG/100MLM N19630 023 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;220MG/100ML; 900MG/100MLM N19630 029 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;300MG/100ML; 200MG/100MLM N19630 036 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;300MG/100ML; 450MG/100MLM N19630 042 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;300MG/100ML; 900MG/100MLM N19630 048 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 200MG/100MLM N19630 012 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 330MG/100MLM N19630 018 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 450MG/100MLM N19630 024 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 900MG/100MLM N19630 030 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;300MG/100ML; 110MG/100MLM N19630 006 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 450MG/100ML* N18362 009 JUL 05, 1983

AP 5GM/100ML;149MG/100ML; 450MG/100ML* N18362 005 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 900MG/100ML* N19691 002 MAR 24, 1988

AP 5GM/100ML;149MG/100ML; 900MG/100ML* N19691 004 MAR 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;74.5MG/100ML; 225MG/100ML* N18365 002 JUL 05, 1983

5GM/100ML;149MG/100ML; 225MG/100ML* N18365 006 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;74.5MG/100ML; 300MG/100ML N18876 001 JAN 17, 1986

5GM/100ML;149MG/100ML; 300MG/100ML* N18876 006 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP TRAVENOL LABS 5GM/100ML;75MG/100ML; 900MG/100ML* N19308 004 APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;224MG/100ML; 450MG/100ML* N18362 006 MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;224MG/100ML; 900MG/100ML* N19691 006 MAR 24, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;224MG/100ML; 225MG/100ML* N18365 008 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;224MG/100ML; 300MG/100ML* N18876 007 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;149MG/100ML; 450MG/100ML* N18362 010 JUL 05, 1983

AP 5GM/100ML;298MG/100ML; 450MG/100ML* N18362 007 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;149MG/100ML; 900MG/100ML* N19691 005 MAR 24, 1988

AP 5GM/100ML;298MG/100ML; 900MG/100ML* N19691 008 MAR 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;149MG/100ML; 225MG/100ML N18365 001

5GM/100ML;298MG/100ML; 225MG/100ML* N18365 009 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;298MG/100ML; 300MG/100ML* N18876 008 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;149MG/100ML; 300MG/100ML N18876 002 JAN 17, 1986

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;224MG/100ML; 450MG/100ML N18362 002

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;224MG/100ML; 900MG/100ML‡ N19691 007 MAR 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;224MG/100ML; 225MG/100ML‡ N18365 003 JUL 05, 1983

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;224MG/100ML; 300MG/100ML N18876 003 JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP TRAVENOL LABS 5GM/100ML;224MG/100ML; 900MG/100ML‡ N19308 006 APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;298MG/100ML; 450MG/100ML N18362 003

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;298MG/100ML; 900MG/100ML‡ N19691 009 MAR 24, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;298MG/100ML; 225MG/100ML‡ N18365 004 JUL 05, 1983

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;298MG/100ML; 300MG/100ML‡ N18876 004 MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 450MG/100ML‡ N18362 008 MAR 28, 1988

AP 5GM/100ML;149MG/100ML; 450MG/100ML‡ N18362 004 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 900MG/100ML‡ N19691 001 MAR 24, 1988

AP 5GM/100ML;149MG/100ML; 900MG/100ML‡ N19691 003 MAR 24, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;74.5MG/100ML; 225MG/100ML‡ N18365 005 MAR 28, 1988

5GM/100ML;149MG/100ML; 225MG/100ML‡ N18365 007 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT LABS 5GM/100ML;74.5MG/100ML; 300MG/100ML‡ N18876 005 MAR 28, 1988

5GM/100ML;149MG/100ML; 300MG/100ML‡ N18876 009 MAR 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;110MG/100ML‡ N19631 011 FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;200MG/100ML‡ N19631 012 FEB 24, 1988

AP KENDALL MCGAN 10GM/100ML;200MG/100ML N19631 013
FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAN 2.5GM/100ML; 110MG/100ML N19631 001
FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAN 2.5GM/100ML; 200MG/100ML N19631 002
FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
KENDALL MCGAN 2.5GM/100ML; 330MG/100ML N19631 003
FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP KENDALL MCGAN 2.5GM/100ML; 450MG/100ML N19631 004
FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAN 2.5GM/100ML; 900MG/100ML N19631 005
FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAN 5GM/100ML;110MG/100ML N19631 006
FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP KENDALL MCGAN 5GM/100ML;200MG/100ML N19631 007
FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP KENDALL MCGAN 5GM/100ML;330MG/100ML N19631 008
FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP KENDALL MCGAN 5GM/100ML;450MG/100ML N19631 009
FEB 24, 1988

AP SQUIBB DIAGS 20G;2MG N87597 001
JUN 01, 1988

DIAZEPAM

TABLET; ORAL
DIAZEPAM
AB PIONEER PHARMS 2MG N70787 001
AUG 02, 1988
AB 5MG N70788 001
AUG 02, 1988
AB 10MG N70776 001
AUG 02, 1988

G-PAM
AB QUANTUM PHARMCS 2MG N72431 001
APR 29, 1988
AB 5MG N72432 001
APR 29, 1988
AB 10MG N72433 001
APR 29, 1988

DIAZOXIDE

CAPSULE; ORAL
PROGLYCEM
MED MKTG SPEC 50MG N17425 001
∂ 100MG N17425 002
/S/SCHERING/ /50MG/ /N17425/001/

INJECTABLE; INJECTION
DIAZOXIDE
AP QUAD PHARMS 15MG/ML N71908 001
JAN 26, 1988

SUSPENSION; ORAL
PROGLYCEM
MED MKTG SPEC 50MG/ML N17453 001
/S/SCHERING/ /50MG/ML/ /N17453/001/

DICLOFENAC SODIUM

TABLET, ENTERIC COATED; ORAL

VOLTAREN

	CIBA PHARM	25MG*	N19201 001	JUL 28, 1988
		50MG*	N19201 002	JUL 28, 1988
		75MG*	N19201 003	JUL 28, 1988

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL

DIBENTYL

AA	MERRELL DON	10MG/5ML	N07961 002	OCT 15, 1984

DICYCLOMINE HCL

AA	BARRE NATL	10MG/5ML	N84479 001	

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL

/HETRAZAN/

	/LEDERLE/LABS/	/50MG/	/N06459/001/	
	∂ LEDERLE LABS	50MG	N06459 001	

DIFLORASONE DIACETATE

CREAM; TOPICAL

/DIFLORASONE DIACETATE/

	/UPJOHN/	/0.05%/	/N19259/001/	/AUG/28/1985/
	∂ UPJOHN	0.05%	N19259 001	AUG 28, 1985

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

/AA/	/LEDERLE/LABS/	/25MG/	/N86874/001/	
/AA/		/50MG/	/N86875/001/	
	∂ LEDERLE LABS	25MG	N86874 001	
	∂	50MG	N86875 001	
>ADD> AA	RICHLYN LABS	25MG	N80807 001	
>DLT> /3/		/25MG/	/N80807/001/	

DISOPYRAMIDE PHOSPHATE

CAPSULE, CONTROLLED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

AB	KV PHARM	EQ 100MG BASE*	N71929 001	AUG 19, 1988

NORPACE CR

AB	SEARLE	EQ 100MG BASE	N18655 001	JUL 20, 1982

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER	80MG/100ML	N19615 001	MAR 27, 1987
AP		160MG/100ML	N19615 002	MAR 27, 1987
AP		320MG/100ML	N19615 003	MAR 27, 1987
		640MG/100ML	N19615 004	MAR 27, 1987
/AP/	/TRAVENOL LABS/	/80MG/100ML/	/N19615/001/	/MAR/27/1987/
/AP/		/160MG/100ML/	/N19615/002/	/MAR/27/1987/
/AP/		/320MG/100ML/	/N19615/003/	/MAR/27/1987/
		/640MG/100ML/	/N19615/004/	/MAR/27/1987/

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

ADAPIN

AB	PENNWALT	EQ 150MG BASE	N16987 007	APR 13, 1987

DOXEPIN HCL

AB	BARR LABS	EQ 25MG BASE*	N71502 001	FEB 18, 1988
AB		EQ 50MG BASE*	N71653 001	FEB 18, 1988
AB		EQ 75MG BASE*	N71654 001	FEB 18, 1988
AB		EQ 100MG BASE*	N71521 001	FEB 18, 1988
AB	CHELSEA LABS	EQ 75MG BASE*	N71763 001	FEB 09, 1988
AB		EQ 150MG BASE*	N71764 001	FEB 09, 1988

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

AB	LEDERLE LABS	EQ 10MG BASE*	N71685 001	JAN 05, 1988
AB		EQ 25MG BASE*	N71686 001	JAN 05, 1988
AB		EQ 50MG BASE*	N71673 001	JAN 05, 1988
AB		EQ 75MG BASE*	N71674 001	JAN 05, 1988
AB		EQ 100MG BASE*	N71675 001	JAN 05, 1988
AB		EQ 150MG BASE*	N71676 001	JAN 05, 1988
AB	PUREPAC PHARM	EQ 75MG BASE*	N72386 001	SEP 08, 1988
AB		EQ 100MG BASE*	N72110 001	SEP 08, 1988
AB		EQ 150MG BASE*	N72387 001	SEP 08, 1988

CONCENTRATE; ORAL

DOXEPIN HCL

AA	MY K LABS	EQ 10MG BASE/ML*	N71918 001	JUL 20, 1988

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	INTERPHARM	EQ 50MG BASE*	N62763 001	SEP 02, 1988
AB		EQ 100MG BASE*	N62763 002	SEP 02, 1988
AB	VITARINE	EQ 50MG BASE*	N62780 001	APR 12, 1988

INJECTABLE; INJECTION

DOXYCYCLINE

AP	BEN VENUE LABS	EQ 100MG BASE/VIAL*	N62569 001	MAR 09, 1988
AP		EQ 200MG BASE/VIAL*	N62569 002	MAR 09, 1988

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	INTERPHARM	EQ 100MG BASE*	N62764 001	SEP 02, 1988

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

AP	ABBOTT LABS	2.5MG/ML*	N71981 001	FEB 29, 1988
AP	ASTRA PHARM PRODS	2.5MG/ML*	N72018 001	OCT 20, 1988
AP		2.5MG/ML*	N72019 001	OCT 19, 1988
AP		2.5MG/ML*	N72020 001	OCT 19, 1988
AP		2.5MG/ML*	N72021 001	OCT 19, 1988
AP	DUPONT CRI CARE	2.5MG/ML*	N71645 001	APR 07, 1988
AP	LUITPOLD PHARMS	2.5MG/ML*	N72123 001	OCT 24, 1988
AP		2.5MG/ML*	N72335 001	OCT 24, 1988
AP	QUAD PHARMS	2.5MG/ML*	N71941 001	AUG 17, 1988
AP		2.5MG/ML*	N71942 001	AUG 17, 1988
AP	SOLOPAK LABS	2.5MG/ML*	N71750 001	SEP 06, 1988
AP		2.5MG/ML*	N71754 001	SEP 06, 1988
AP		2.5MG/ML*	N71755 001	SEP 06, 1988

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

AP	ABBOTT LABS	2.5MG/ML; EQ 0.05MG BASE/ML*	N71982 001	MAY 04, 1988

INNOVAR

AP	JANSSEN PHARMA	2.5MG/ML; EQ 0.05MG BASE/ML*	N16049 001	

DYDROGESTERONE

TABLET; ORAL

GYNOREST

∂	KALI DUPHAR	5MG	N17388 001
∂		10MG	N17388 002

/TABLET;ORAL/
/GYNOREST/
/REID/ROWELL/ /5MG/ /10MG/ /N17388/001/ /N17388/002/

EDETATE CALCIUM DISODIUM

TABLET; ORAL
CALCIUM DISODIUM VERSENATE

	∂ RIKER LABS	500MG	N08922 002

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
REVERSOL

AP	ORGANON	10MG/ML	N89624 001 MAY 13, 1988

ENALAPRIL MALEATE

TABLET; ORAL
VASOTEC

	MS&D RES LABS	2.5MG	N18998 005 JUL 26, 1988

ENALAPRILAT

INJECTABLE; INJECTION
VASOTEC

	MS&D RES LABS	1.25MG/ML	N19309 001 FEB 09, 1988

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE

AP	ABBOTT LABS	0.005MG/ML;0.5%	N89635 001 JUN 21, 1988
AP		0.005MG/ML;1%	N89649 001 JUN 21, 1988
AP		0.005MG/ML;1.5%	N89645 001 JUN 21, 1988
AP		0.005MG/ML;1.5%	N89650 001 JUN 21, 1988
AP		0.005MG/ML;2%	N89651 001 JUN 21, 1988
AP		0.01MG/ML;1%	N89644 001 JUN 21, 1988
AP		0.01MG/ML;2%	N89646 001 JUN 21, 1988

LIDOCAINE HCL W/ EPINEPHRINE

	∂ LEMMON	0.01MG/ML;1%	N85463 001

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE

AP	ASTRA PHARM PRODS	0.005MG/ML;0.5%	N06488 013
AP		0.005MG/ML;1%	N06488 018 NOV 13, 1986
AP		0.005MG/ML;2%	N06488 019 NOV 13, 1986

ERGOLOID MESYLATES

TABLET; ORAL
ERGOLOID MESYLATES

	CHELSEA LABS	1MG	N88207 001 MAR 22, 1984

SERIMAL

AB	CHELSEA LABS	1MG	N88207 001 MAR 22, 1984

TABLET; SUBLINGUAL
ERGOLOID

	RIKER LABS	0.5MG	N84868 001
		1MG	N85809 001
	∂ RIKER LABS	0.5MG	N84868 001
	∂	1MG	N85809 001

ERGOLOID MESYLATES

	CHELSEA LABS	0.5MG	N86189 001
		1MG	N86188 001

SERIMAL

AA	CHELSEA LABS	0.5MG	N86189 001
AA		1MG	N86188 001

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN

AT	NASKA PHARMA	2%	N62957 001 JUL 21, 1988

ETS-2%

AT	PADDOCK LABS	2%	N62687 001 FEB 05, 1988

TABLET, ENTERIC COATED; ORAL
E-BASE

AB	BARR LABS	500MG	N62999 001 NOV 25, 1988

ERY-TAB

AB	ABBOTT LABS	500MG	N62298 002

25

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL
ILOSONE SULFA
LILLY — EQ 125MG BASE/5ML; EQ 600MG BASE/5ML — N50599 001 SEP 16, 1988

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL
ERYTHROMYCIN ETHYLSUCCINATE
AB MYLAN PHARMS — EQ 400MG BASE — N62847 001 SEP 14, 1988

TABLET, CHEWABLE; ORAL
ERYPED
AB ABBOTT LABS — EQ 200MG BASE — N50297 003 JUL 05, 1988

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL
AB BARR LABS — EQ 200MG BASE/5ML; EQ 600MG BASE/5ML — N62759 001 MAY 20, 1988

ERYZOLE
AB ALRA LABS — EQ 200MG BASE/5ML; EQ 600MG BASE/5ML — N62758 001 JUN 15, 1988

PEDIAZOLE
AB ROSS LABS — EQ 200MG BASE/5ML; EQ 600MG BASE/5ML — N50529 001

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROCIN
AP ABBOTT LABS — EQ 500MG BASE/VIAL — N62586 001 JAN 04, 1988
AP — EQ 1GM BASE/VIAL — N62586 002 JAN 04, 1988

ERYTHROMYCIN STEARATE

TABLET; ORAL
/[illegible]/
/AA/ /BRISTOL/LABS/ /EQ 250MG BASE/ /N61304/001/
/AA/ /EQ 250MG BASE/ /N61887/001/
∂ BRISTOL LABS — EQ 250MG BASE — N61304 001
∂ — EQ 250MG BASE — N61887 001

ERYPAR
/AA/ /PARKE/DAVIS/ /EQ 250MG BASE/ /N62032/001/
/AA/ /EQ 500MG BASE/ /N62032/002/
∂ PARKE DAVIS — EQ 250MG BASE — N62032 001
∂ — EQ 500MG BASE — N62032 002

ERYTHROCIN STEARATE
/AA/ /ABBOTT/LABS/ /EQ 125MG BASE/ /N60359/002/
∂ ABBOTT LABS — EQ 125MG BASE — N60359 002

ERYTHROMYCIN STEARATE
/AA/ /LEDERLE/LABS/ /EQ 250MG BASE/ /N62089/001/
/AA/ /EQ 500MG BASE/ /N62089/002/
∂ LEDERLE LABS — EQ 250MG BASE — N62089 001
∂ — EQ 500MG BASE — N62089 002

/[illegible]/
/AA/ /PFIZER/LABS/ /EQ 500MG BASE/ /N61791/002/
∂ PFIZER LABS — EQ 500MG BASE — N61791 002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC
DUPONT CRI CARE — 10MG/ML — N19386 001 AUG 15, 1988

ESTRADIOL

FILM, CONTROLLED RELEASE; PERCUTANEOUS
ESTRADERM
CIBA PHARM — 0.05MG/24HR — N19081 002 SEP 10, 1986
0.1MG/24HR — N19081 003 SEP 10, 1986
/[illegible]/ /N19081/002/ /SEP/10/1986/
/[illegible]/ /N19081/003/ /SEP/10/1986/

ESTRONE

INJECTABLE; INJECTION

ESTRONE

/BP/	/STERIS/LABS/	/1MG/ML/	/N85239/001/	
	STERIS LABS	1MG/ML	N85239 001	

THEELIN

/BP/	/PARKE/DAVIS/	/1MG/ML/	/N03977/001/	
/BP/		/5MG/ML/	/N03977/003/	
	∂ PARKE DAVIS	1MG/ML	N03977 001	
	∂	5MG/ML	N03977 003	

ETHINYL ESTRADIOL

TABLET; ORAL

/LYNORAL/

/BP/	/ORGANON/	/0.01MG/	/N05490/002/	
		/0.05MG/	/N05490/003/	
	∂ ORGANON	0.01MG	N05490 003	
	∂	0.05MG	N05490 002	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

AB	SEARLE PHARMS	0.035MG;1MG[M]	N71480 001 APR 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.035MG;0.5MG AND 1MG[M]	N71043 001 APR 01, 1988

ORTHO-NOVUM 10/11-21

AB	ORTHO PHARM	0.035MG;0.5MG AND 1MG	N18354 001 JAN 11, 1982

TABLET; ORAL-28

NORETHIN 1/35E-28

AB	SEARLE PHARMS	0.035MG;1MG[M]	N71481 001 APR 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.035MG;0.5MG AND 1MG[M]	N71044 001 APR 01, 1988

ORTHO-NOVUM 10/11-28

AB	ORTHO PHARM	0.035MG;0.5MG AND 1MG	N18354 002 JAN 11, 1982

ETHIODIZED OIL

/INJECTABLE;/INJECTION/

/ETHIODOL/

	/FOUGERA/	/99%/	/N09196/001/

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

ETHIODOL

	SAVAGE LABS	99%	N09190 001

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB	AM THERPTCS	EQ 200MG BASE[M]	N72307 001 AUG 22, 1988
AB		EQ 300MG BASE[M]	N72308 001 AUG 22, 1988
AB	CORD LABS	EQ 200MG BASE[M]	N72394 001 OCT 17, 1988
AB		EQ 300MG BASE[M]	N72395 001 OCT 17, 1988
AB	HALSEY DRUG	EQ 200MG BASE[M]	N72355 001 AUG 17, 1988 : JUL 05, 1988
AB		EQ 300MG BASE[M]	N72356 001 AUG 17, 1988 : JUL 05, 1988
AB	PAR PHARM	EQ 200MG BASE[M]	N72437 001 AUG 22, 1988
AB		EQ 300MG BASE[M]	N72438 001 AUG 22, 1988
AB	QUANTUM PHARMCS	EQ 200MG BASE[M]	N72214 001 AUG 17, 1988 : APR 14, 1988
AB		EQ 300MG BASE[M]	N71738 001 AUG 17, 1988 : APR 14, 1988
AB	WATSON LABS	EQ 200MG BASE[M]	N72294 001 AUG 17, 1988 : JUL 08, 1988
AB		EQ 300MG BASE[M]	N72293 001 AUG 17, 1988 : JUL 08, 1988

NALFON

AB	DISTA PRODS	EQ 300MG BASE	N17604 002

NALFON 200

AB	DISTA PRODS	EQ 200MG BASE	N17604 003

TABLET; ORAL

FENOPROFEN CALCIUM

AB	AM THERPTCS	EQ 600MG BASE[M]	N72309 001 AUG 17, 1988 : JUN 16, 1988
AB	CHELSEA LABS	EQ 600MG BASE[M]	N72407 001 AUG 17, 1988 : JUN 13, 1988
AB	CORD LABS	EQ 600MG BASE[M]	N72396 001 OCT 17, 1988
AB	DANBURY PHARMA	EQ 600MG BASE[M]	N72602 001 OCT 11, 1988
AB	HALSEY DRUG	EQ 600MG BASE[M]	N72357 001 AUG 17, 1988 : JUL 05, 1988

FENOPROFEN CALCIUM

TABLET; ORAL
FENOPROFEN CALCIUM

AB	LEDERLE LABS	EQ 600MG BASE*	N72326 001
		AUG 17, 1988 :	APR 20, 1988
AB	MYLAN PHARMS	EQ 600MG BASE*	N72267 001
		AUG 17, 1988 :	JUN 08, 1988
AB	PAR PHARM	EQ 600MG BASE*	N72429 001
		AUG 17, 1988 :	JUL 19, 1988
AB	PHARM BASICS	EQ 600MG BASE*	N72362 001
		AUG 17, 1988 :	JUN 16, 1988
AB	PUREPAC PHARM	EQ 600MG BASE*	N72274 001
			MAY 02, 1988
AB	QUANTUM PHARMCS	EQ 600MG BASE*	N72194 001
		AUG 17, 1988 :	APR 14, 1988
AB	WATSON LABS	EQ 600MG BASE*	N72165 001
		AUG 17, 1988 :	JUL 08, 1988
AB	ZENITH LABS	EQ 600MG BASE*	N72557 001
			AUG 29, 1988

NALFON

AB	DISTA PRODS	EQ 600MG BASE	N17710 001

FERROUS SULFATE; FOLIC ACID

	/CAPSULE;ORAL/		
	/FOLVRON/		
	/LEDERLE LABS/	/182MG;0.33MG/	/N06012 003/
	∂ LEDERLE LABS	182MG;0.33MG	N06012 003

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

	RIKER LABS	50MG*	N18830 004
			AUG 23, 1988
		150MG*	N18830 003
			JUN 03, 1988

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

AT	G&W LABS	0.01%*	N89526 001
			JUL 26, 1988
AT		0.025%*	N89525 001
			JUL 26, 1988

FLUOCINOLONE ACETONIDE

OIL; TOPICAL
DERMA-SMOOTHE/FS

	HILL DERM	0.01%*	N19452 001
			FEB 03, 1988

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE

AT	G&W LABS	0.025%*	N89524 001
			JUL 26, 1988

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

AB	CLAY PARK LABS	0.05%*	N71790 001
		JUL 13, 1988 :	APR 25, 1988

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP	BEN VENUE LABS	50MG/ML*	N89508 001
			JAN 26, 1988

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
FLUPHENAZINE HCL

AP	QUAD PHARMS	2.5MG/ML*	N89800 001
			JUN 08, 1988

TABLET; ORAL
FLUPHENAZINE HCL

AB	MYLAN PHARMS	1MG*	N89801 001
			AUG 12, 1988
AB		2.5MG*	N89802 001
			AUG 12, 1988
AB		5MG*	N89803 001
			AUG 12, 1988
AB		10MG*	N89804 001
			AUG 12, 1988

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL
FLUPHENAZINE HCL

AB	PAR PHARM	1MG	N89740 001 AUG 25, 1988
AB		2.5MG	N89741 001 AUG 25, 1988
AB		5MG	N89742 001 AUG 25, 1988
AB		10MG	N89743 001 AUG 25, 1988
	PERMITIL		
BP	SCHERING	2.5MG	N12034 004
BP		5MG	N12034 005
BP		10MG	N12034 006
/A/		/2.5MG/	/N12034/004/
/A/		/5MG/	/N12034/005/
/A/		/10MG/	/N12034/006/

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

AB	HALSEY DRUG	15MG	N71808 001 JAN 07, 1988
AB		30MG	N71809 001 JAN 07, 1988
AB	SUPERPHARM	15MG	N71659 001 AUG 04, 1988
AB		30MG	N71660 001 AUG 04, 1988

FLURBIPROFEN

TABLET; ORAL
ANSAID

	UPJOHN	50MG	N18766 002 OCT 31, 1988
		100MG	N18766 003 OCT 31, 1988

FOLIC ACID

TABLET; ORAL
FOLIC ACID

/AA/	/BARR LABS/	/1MG/	/N89177/001/ /JAN 08, 1986/
	∂ BARR LABS	1MG	N89177 001 JAN 08, 1986

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

/AP/	/PARKE/DAVIS/	/10MG/ML/	/N18420/001/ /FEB 26, 1982/
AP	WARNER CHILCOTT	10MG/ML	N18420 001 FEB 26, 1982

TABLET; ORAL
FUROSEMIDE

AB	BARR LABS	80MG	N70100 001 JAN 26, 1988
AB	DANBURY PHARMA	80MG	N71594 001 FEB 09, 1988

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION
MAGNEVIST

	BERLEX LABS	469.01MG/ML	N19596 001 JUN 02, 1988

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67

	/MEDI PHYSICS/	/1MCI/ML/	/N17700/001/
	∂ MEDI PHYSICS	1MCI/ML	N17700 001

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

>ADD>	AT	PACO RES	EQ 3MG BASE/ML	N62932 001 NOV 07, 1988
>ADD>				

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
PRED-G

	ALLERGAN PHARMS	EQ 0.3% BASE;1%	N50586 001 JUN 10, 1988

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP	ABBOTT LABS	0.2MG/ML[M]	N89393 001 JUN 15, 1988

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML[M]	N62818 001 OCT 11, 1988

GUANABENZ ACETATE

TABLET; ORAL

	WYTENSIN		
	WYETH AYERST LABS	EQ 16MG BASE	N16567 003 SEP 07, 1982
	∂ WYETH AYERST LABS	EQ 16MG BASE	N18587 003 SEP 07, 1982

HALOPERIDOL

TABLET; ORAL
HALDOL SOLUTAB

	HALDOL	1MG	N17079 001
	∂ MCNEIL PHARM	1MG	N17079 001
	HALOPERIDOL		
AB	BARR LABS	5MG[M]	N71212 001 JAN 07, 1988
AB		10MG[M]	N71173 001 JAN 07, 1988
AB		20MG[M]	N71177 001 JAN 07, 1988
AB	BOLAR PHARM	0.5MG[M]	N71571 001 JUN 03, 1988
AB		1MG[M]	N71572 001 JUN 03, 1988
AB		2MG[M]	N71573 001 JUN 03, 1988
AB		5MG[M]	N71374 001 JUN 03, 1988
AB		10MG[M]	N71375 001 JUN 03, 1988
AB		20MG[M]	N71376 001 JUN 03, 1988

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB	CORD LABS	10MG[M]	N71210 001 MAR 11, 1988
AB		20MG[M]	N71211 001 MAR 11, 1988

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALDOL

	MCNEIL LABS	EQ 2MG BASE/ML	N15922 001
AA	MCNEIL PHARM	EQ 2MG BASE/ML	N15922 001
	HALOPERIDOL INTENSOL		
AA	ROXANE LABS	EQ 2MG BASE/ML[M]	N72045 001 APR 12, 1988

INJECTABLE; INJECTION
HALOPERIDOL

AP	LEMMON	EQ 5MG BASE/ML[M]	N70713 001 MAY 17, 1988
AP		EQ 5MG BASE/ML[M]	N70714 001 MAY 17, 1988
AP		EQ 5MG BASE/ML[M]	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION
HEP FLUSH KIT IN PLASTIC CONTAINER

AP	LYPHOMED	10 UNITS/ML[M]	N17029 017 DEC 05, 1985
AP		100 UNITS/ML[M]	N17029 018 DEC 05, 1985
	HEPARIN LOCK FLUSH		
	ABBOTT LABS	100 UNITS/ML	N05264 010
	∂ ABBOTT LABS	100 UNITS/ML	N05264 010
	HEPARIN LOCK FLUSH IN PLASTIC CONTAINER		
AP	ABBOTT LABS	10 UNITS/ML	N05264 015 MAY 21, 1985
AP		100 UNITS/ML	N05264 016 MAY 21, 1985
	HEPARIN SODIUM		
	LYPHOMED	5,000 UNITS/ML	N17979 003
	∂ LYPHOMED	5,000 UNITS/ML	N17979 003

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	LYPHOMED	1,000 UNITS/ML*	N17029 013 DEC 05, 1985
AP		5,000 UNITS/ML*	N17029 014 DEC 05, 1985
AP		10,000 UNITS/ML*	N17029 015 DEC 05, 1985
AP		20,000 UNITS/ML*	N17029 016 DEC 05, 1985

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

/AP/	/ABBOTT/LABS/	/10,000 UNITS/100ML/	/N19339/003/ /MAR/27,/1985/
	ə ABBOTT LABS	10,000 UNITS/100ML	N19339 003 MAR 27, 1985

HEPARIN SODIUM 1000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER	200 UNITS/100ML	N18609 001 APR 28, 1982
/AP/	/TRAVENOL/LABS/	/200 UNITS/100ML/	/N16699/001/ /APR/28,/1982/

/HEPARIN SODIUM 12,000 UNITS IN DEXTROSE 5% IN PLASTIC/ /CONTAINER/

/AP/	/ABBOTT/LABS/	/5,000 UNITS/100ML/	/N19339/001/ /MAR/27,/1985/
	ə ABBOTT LABS	5,000 UNITS/100ML	N19339 001 MAR 27, 1985

HEPARIN SODIUM 2000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER	200 UNITS/100ML	N18609 002 APR 28, 1982

/HEPARIN SODIUM 20000 UNITS AND SODIUM CHLORIDE 0.9% IN/ /PLASTIC CONTAINER/

/AP/	/TRAVENOL/LABS/	/200 UNITS/100ML/	/N16699/002/ /APR/28,/1982/

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

/AP/	/ABBOTT/LABS/	/5,000 UNITS/100ML/	/N19339/004/ /MAR/27,/1985/
/AP/		/10,000 UNITS/100ML/	/N19339/002/ /MAR/27,/1985/
	ə ABBOTT LABS	5,000 UNITS/100ML	N19339 004 MAR 27, 1985
	ə	10,000 UNITS/100ML	N19339 002 MAR 27, 1985

HEPARIN SODIUM 5000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER	500 UNITS/100ML	N18609 003 APR 28, 1982

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 5000 UNITS AND SODIUM CHLORIDE 0.9% IN

/AP/	/TRAVENOL/LABS/	/500 UNITS/100ML/	/N16699/003/ /APR/28,/1982/

/INJECTION,SODIUM PRESERVATIVE FREE/

/AP/	/ORGANON/	/1,000 UNITS/ML/	
/AP/		/5,000 UNITS/ML/	
/AP/		/10,000 UNITS/ML/	
	ə ORGANON	1,000 UNITS/ML	APR 11, 1986
	ə	5,000 UNITS/ML	N00552 012 APR 11, 1986
	ə	10,000 UNITS/ML	N00552 013 APR 11, 1986

SODIUM HEPARIN

/AP/	/LYPHOMED/	/5,000 UNITS/ML/	/N17033/002/
/AP/		/10,000 UNITS/ML/	/N17033/003/
/AP/		/20,000 UNITS/ML/	/N17033/004/
	ə LYPHOMED	5,000 UNITS/ML	N17033 002
	ə	10,000 UNITS/ML	N17033 003
	ə	20,000 UNITS/ML	N17033 004

HEXOCYCLIUM METHYLSULFATE

/TABLET;/ORAL/ /TRAL/

/S/ABBOTT/LABS/	/25MG/	/N10599/001/

TABLET; ORAL

TRAL

ABBOTT LABS	25MG	N10599 001

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

/AA/	/PUREPAC/PHARM/	/50MG/	/N88178/001/ /AUG/15,/1983/
	ə PUREPAC PHARM	50MG	N88178 001 AUG 15, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRAL

AB	REID ROWELL	25MG;25MG	N87608 001	FEB 08, 1982
AB		50MG;50MG	N87213 001	FEB 08, 1982
/$/		/25MG;25MG/	/N87608/001/	/FEB/08,/1982/
/$/		/50MG;50MG/	/N87213/001/	/FEB/08,/1982/

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

/BP/	/REID/ROWELL/	/25MG;15MG;0.1MG/	/N87216/001/	
BP	REID ROWELL	25MG;15MG;0.1MG	N88376 001	OCT 28, 1983
∂		25MG;15MG;0.1MG	N87210 001	
/$/		/25MG;15MG;0.1MG/	/N88376/001/	/OCT/28,/1983/

/RESERPINE;HYDROCHLOROTHIAZIDE;AND/HYDRALAZINE/HCL/

/BP/	/LEDERLE/LABS/	/25MG;15MG;0.1MG/	/N87709/001/	/MAY/13,/1982/
∂	LEDERLE LABS	25MG;15MG;0.1MG	N87709 001	MAY 13, 1982

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

AA	MY K LABS	50MG/5ML	N89661 001	JUN 20, 1988
AA	ROXANE LABS	50MG/5ML	N88587 001	JUL 02, 1984

TABLET; ORAL

HYDROCHLOROTHIAZIDE

/AA/	/BANMAX/PHARMS/	/25MG/	/N86369/001/	
/AA/		/50MG/	/N83554/001/	
∂	BANMAX PHARMS	25MG	N86369 001	
∂		50MG	N83554 001	
>_ADD_> AB	WARNER CHILCOTT	25MG	N87586 001	MAY 03, 1982
>_ADD_> AB		50MG	N87587 001	MAY 03, 1982

HYDROCHLOROTHIAZIDE

TABLET; ORAL

>_DLT_> /AA/	/PARKE/DAVIS/	/25MG/	/N87586/001/	/MAY/03,/1982/
>_DLT_> /AA/		/50MG/	/N87587/001/	/MAY/03,/1982/

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

	/SCHERING/	/25MG;400MG/	/N19046/004/	/APR/06,/1987/
	∂ SCHERING	25MG;400MG	N19046 004	APR 06, 1987

TRANDATE HCT

AB	GLAXO	25MG;100MG	N19174 001	APR 10, 1987
AB		25MG;200MG	N19174 002	APR 10, 1987
AB		25MG;300MG	N19174 003	APR 10, 1987
>_ADD_>	∂	25MG;400MG	N19174 004	APR 10, 1987

/TRANDATE-HCT/

/AB/	/GLAXO/	/25MG;100MG/	/N19174/001/	/APR/10,/1987/
/AB/		/25MG;200MG/	/N19174/002/	/APR/10,/1987/
/AB/		/25MG;300MG/	/N19174/003/	/APR/10,/1987/
>_DLT_> /AB/		/25MG;400MG/	/N19174/004/	/APR/10,/1987/

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	NOVOPHARM	15MG;250MG	N71819 001	APR 08, 1988
AB		25MG;250MG	N71820 001	APR 08, 1988
AB		30MG;500MG	N71821 001	APR 08, 1988
AB		50MG;500MG	N71822 001	APR 08, 1988

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

~~AB~~	~~PUREPAC PHARM~~	~~250MG;500MG~~	~~A166664 001 APR 24, 1986~~
	∂ PUREPAC PHARM	50MG;500MG	A70689 001 APR 24, 1986
AB	NATSON LABS	15MG;250MG	A71920 001 AUG 29, 1988
AB		25MG;250MG	A71921 001 AUG 29, 1988
AB		30MG;500MG	A71922 001 AUG 29, 1988
AB		50MG;500MG	A71923 001 AUG 29, 1988
AB	ZENITH LABS	15MG;250MG	A71458 001 MAR 08, 1988
AB		25MG;250MG	A71459 001 MAR 08, 1988
AB		30MG;500MG	A71460 001 MAR 08, 1988
AB		50MG;500MG	A71461 001 MAR 08, 1988

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

~~PINDOLOL~~	~~SANDOZ PHARMS~~	~~25MG;5MG~~	~~A18872 001 JUL 22, 1987~~
	∂ SANDOZ PHARMS	25MG;5MG	A18872 001 JUL 22, 1987
		~~25MG;10MG~~	~~A18872 002 JUL 22, 1987~~
	∂	25MG;10MG	A18872 002 JUL 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

AB	SIDMAK LABS	25MG;40MG	A72042 001 MAR 14, 1988
AB		25MG;80MG	A72043 001 MAR 14, 1988
AB	WARNER CHILCOTT	25MG;40MG	A71771 001 JAN 26, 1988
AB		25MG;80MG	A71772 001 JAN 26, 1988

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

~~∂~~	~~PHARMAFAIR~~	~~25MG;0.125MG~~	~~A85421 001~~
	∂ PHARMAFAIR	25MG;0.125MG	A85421 001

RESERPINE AND HYDROCHLOROTHIAZIDE

~~BP~~	~~BARR LABS~~	~~25MG;0.125MG~~	~~A84580 001~~
~~BP~~		~~50MG;0.125MG~~	~~A84579 001~~
	∂ BARR LABS	25MG;0.125MG	A84580 001
	∂	50MG;0.125MG	A84579 001

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

~~AB~~	~~LEDERLE LABS~~	~~25MG;25MG~~	~~A87511 001~~
	∂ LEDERLE LABS	25MG;25MG	A87511 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	VITARINE	25MG;50MG	A71737 001 FEB 12, 1988

TABLET; ORAL

MAXZIDE-25MG

	MYLAN PHARMS	25MG;37.5MG	A19129 003 MAY 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	CORD LABS	50MG;75MG	A72011 001 JUN 17, 1988
AB	DANBURY PHARMA	50MG;75MG	A71969 001 APR 17, 1988 : JAN 15, 1988
AB	PAR PHARM	50MG;75MG	A72337 001 MAY 11, 1988
AB	QUANTUM PHARMCS	50MG;75MG	A71980 001 APR 17, 1988 : FEB 01, 1988
>ADD> AB	NATSON LABS	50MG;75MG	A71851 001 >ADD> NOV 30, 1988

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	NASKA PHARMA	1%	N89706 001 MAR 10, 1988
AT		2.5%	N89682 001 MAR 10, 1988

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE			
AT	NMC LABS	1%		N87795 001 MAY 03, 1983
	HYDROTEX			
AT	SYOSSET LABS	1%[RX]		N87427 001 APR 04, 1988
/AT/	/HYNAS/ /NMC/LABS/	/1%/		/N87795/001/ /MAY/03,/1983/

LOTION; TOPICAL

	BETA-HC			
AT	BETA DERM	1%[RX]		N89495 001 JAN 25, 1988
	HYDROCORTISONE			
AT	NASKA PHARMA	1%[RX]		N89705 001 APR 25, 1988

OINTMENT; TOPICAL

	HC (HYDROCORTISONE)			
/AT/	/C&M/PHARMA/	/0.5%/		/N80481/001/ /N80481/002/
/AT/		/1%/		
AT	C&M PHARMA	1%		N80481 002
	HYDROCORTISONE			
AT	NASKA PHARMA	1%[RX]		N89704 001 MAR 10, 1988

TABLET; ORAL

	HYDROCORTISONE			
/AP/	/BARR/LABS/	/20MG/		/N83999/001/
	∂ BARR LABS	20MG		N83999 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE			
AT	STERIS LABS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML[RX]		N62874 001 MAY 11, 1988

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HYDROCORTISONE ACETATE			
/AT/	/THAMES/PHARMA/	/1%/		/N89472/001/ /JUN/13,/1988/

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL; TOPICAL

	EPIFOAM			
AT	REED & CARNRICK	1%;1%[RX]		N86457 001
	HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%			
AT	COPLEY PHARM	1%;1%[RX]		N89440 001 MAY 17, 1988

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

	CARMOL HC			
AT	SYNTEX LABS	1%;10%[RX]		N80505 001
	HYDROCORTISONE ACETATE			
AT	THAMES PHARMA	1%;10%		N89472 001 JUN 13, 1988

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL

	HYDROCORTISONE BUTYRATE			
AT	GIST BROCADES	0.1%		N19116 001 FEB 25, 1987
	/Locoid/ /GIST/BROCADES/	/0.1%/		/N19116/001/ /FEB/25,/1987/
	LOCOID			
AT	OWEN LABS	0.1%[RX]		N19819 001 OCT 15, 1988

HYDROFLUMETHIAZIDE

TABLET; ORAL

	HYDROFLUMETHIAZIDE			
/AB/	/BOLAR/PHARM/	/50MG/		/N88031/001/ /APR/06,/1983/
	∂ BOLAR PHARM	50MG		N88031 001 APR 06, 1983

> ADD > ## HYDROXYPROPYL CELLULOSE

> ADD > INSERT; OPHTHALMIC

> ADD >	LACRISERT			
> ADD >	MS&D RES LABS	5MG		N18771 001

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

/AA/	/ALTANA/	/25MG/ML/	/N87273/001/ /APR/20,/1982/
/AA/		/50MG/ML/	/N87273/002/ /APR/20,/1982/
	∂ ALTANA	25MG/ML	N87273 001 APR 20, 1982
	∂	50MG/ML	N87273 002 APR 20, 1982

SYRUP; ORAL
HYDROXYZINE HCL

AA	NASKA PHARMA	10MG/5ML[DM]	N88785 001 FEB 03, 1988

TABLET; ORAL
HYDROXYZINE HCL

AB	HALSEY DRUG	10MG[DM]	N89366 001 MAY 02, 1988
AB		25MG[DM]	N89117 001 MAY 02, 1988
AB		50MG[DM]	N89396 001 MAY 02, 1988

IBUPROFEN

TABLET; ORAL
IBU-TAB

AB	ALRA LABS	400MG[DM]	N71058 001 AUG 11, 1988
AB		600MG[DM]	N71059 001 AUG 11, 1988
AB		800MG[DM]	N71965 001 AUG 11, 1988

IBUPROFEN

AB	HALSEY DRUG	800MG[DM]	N72137 001 FEB 05, 1988
AB	INVAMED	400MG[DM]	N72064 001 JAN 14, 1988
AB		600MG[DM]	N72065 001 JAN 14, 1988
AB		800MG[DM]	N71938 001 JAN 14, 1988
AB	MEDICOPHARMA	400MG[DM]	N71644 001 FEB 01, 1988
AB	PRIVATE FMLTNS	800MG[DM]	N72300 001 JUL 01, 1988
AB	PUREPAC PHARM	800MG[DM]	N71964 001 FEB 01, 1988

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HCL

/AA/	/LEDERLE/LABS/	/10MG/	/N86268/001/
/AA/		/25MG/	/N86267/001/
/AA/		/50MG/	/N86268/001/
	∂ LEDERLE LABS	10MG	N86269 001
	∂	25MG	N86267 001
	∂	50MG	N86268 001
	/BANMAX/		
/AA/	/BANMAX/PHARMS/	/10MG/	/N83827/001/
/AA/		/25MG/	/N83827/002/
/AA/		/50MG/	/N83827/003/
	∂ BANMAX PHARMS	10MG	N83827 001
	∂	25MG	N83827 002
	∂	50MG	N83827 003

INDIUM IN-111 OXYQUINOLINE

/INJECTABLE;/INJECTION/
/INDIUM/IN-111/OXYQUINOLINE/

/AMERSHAM/	/N/A/	/N19044/001/ /DEC/23,/1985/

INJECTABLE; INTRATHECAL
INDIUM IN-111 OXYQUINOLINE

AMERSHAM	1MCI/ML	N19044 001 DEC 23, 1985

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN

∂ B-D MICROBIOL SYS	10MG/VIAL	N11525 003
	25MG/VIAL	N11525 001
∂	40MG/VIAL	N11525 004
	50MG/VIAL	N11525 002
/H.YNSN/WES/A/DUN/	/10MG/VIAL/	/N11525/003/
	/40MG/VIAL/	/N11525/004/

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	NOVOPHARM	25MG[DM]	N71342 001 APR 18, 1988
AB		50MG[DM]	N71343 001 APR 18, 1988

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN
AB VITARINE 25MG N71711 001 JUL 05, 1988
AB 50MG N71712 001 JUL 05, 1988

INSULIN PORK

INJECTABLE; INJECTION
ILETIN
LILLY 500 UNITS/ML N17931 001

IOHEXOL

INJECTABLE; INJECTION
OMNIPAQUE 140
STERLING DRUG 30.2% N18956 005 NOV 30, 1988
OMNIPAQUE 180
STERLING DRUG 38.8% N18956 001 DEC 26, 1985

IOTHALAMATE MEGLUMINE

SOLUTION; INTRAVESICAL
CYSTO-CONRAY II
MALLINCKRODT 17.2% N17057 002

SOLUTION; INTRAVESICAL, URETERAL
CYSTO-CONRAY
MALLINCKRODT 43% N17057 001

IRON DEXTRAN

INJECTABLE; INJECTION
AP FISONS EQ 50MG IRON/ML N17807 001
∂ FISONS

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
> ADD > AN DEY LABS 0.17% N87390 001
ISOETHARINE HCL S/F
> ADD > AN DEY LABS 0.08% N89817 001 NOV 22, 1988
> ADD > AN 0.1% N39818 001 NOV 22, 1988
> ADD > AN 0.17% N89819 001 NOV 22, 1988
> ADD > AN 0.25% N89820 001 NOV 22, 1988

ISONIAZID

INJECTABLE; INJECTION
ISONIAZID
AP QUAD PHARMS 100MG/ML N89816 001 OCT 28, 1988
NYDRAZID
AP SQUIBB 100MG/ML N08662 001

TABLET; ORAL
DON-ISONIAZID
AA DON PHARMS 300MG N80330 002
∂ DON PHARMS 300MG
LANIAZID
AA LANNETT 300MG N89776 001 JUN 13, 1988

ISOSORBIDE DINITRATE

CAPSULE, CONTROLLED RELEASE; ORAL
DILATRATE-SR
BC REED & CARNRICK 40MG N19790 001 SEP 02, 1988
ISORDIL
BC WYETH AYERST LABS 40MG N12882 002 JUL 29, 1988

ISOSORBIDE DINITRATE

TABLET; ORAL

	ISORDIL			
AB	NYETH AYERST LABS	5MG		N12093 007 JUL 29, 1988
AB		10MG		N12093 002 JUL 29, 1988
AB		20MG		N12093 006 JUL 29, 1988
AB		30MG		N12093 005 JUL 29, 1988
		40MG		N12093 001 JUL 29, 1988
	ISOSORBIDE DINITRATE			
AB	BARR LABS	30MG		N87564 001 SEP 18, 1986
AB	CORD LABS	5MG		N86221 001 JAN 07, 1988
AB		10MG		N86223 001 JAN 07, 1988
AB		20MG		N89367 001 APR 07, 1988
AB	DANBURY PHARMA	5MG		N86034 001 JAN 06, 1988
AB		10MG		N86032 001 JAN 07, 1988
AB	PAR PHARM	30MG		N87946 001 JAN 12, 1989

TABLET; SUBLINGUAL

	ISORDIL			
AB	NYETH AYERST LABS	2.5MG		N12940 004 JUL 29, 1988
AB		5MG		N12940 003 JUL 29, 1988
AB		10MG		N12940 005 JUL 29, 1988
	ISOSORBIDE DINITRATE			
AB	BARR LABS	10MG		N87545 001 SEP 18, 1986
AB	CORD LABS	2.5MG		N86225 001 FEB 19, 1988
AB		5MG		N86222 001 FEB 19, 1988
AB	DANBURY PHARMA	2.5MG		N86033 001 FEB 26, 1988
AB		5MG		N86031 001 SEP 29, 1987

ISOSORBIDE DINITRATE

TABLET, CONTROLLED RELEASE; ORAL

	ISORDIL			
	NYETH AYERST LABS	40MG		N12882 001 JUL 29, 1988

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	KETALAR			
AP	PARKE DAVIS	EQ 10MG BASE/ML		N16812 001
AP		EQ 50MG BASE/ML		N16812 002
AP		EQ 100MG BASE/ML		N16812 003
	KETAMINE HCL			
AP	QUAD PHARMS	EQ 10MG BASE/ML		N71949 001 APR 11, 1988
AP		EQ 50MG BASE/ML		N71950 001 APR 11, 1988
AP		EQ 100MG BASE/ML		N71951 001 APR 11, 1988

LACTULOSE

SYRUP; ORAL

	CHRONULAC			
AA	MERRELL DOW	10GM/15ML		N17884 001
	CONSTILAC			
AA	ALRA LABS	10GM/15ML		N71054 001 JUL 26, 1988
	CONSTULOSE			
AA	BARRE NATL	10GM/15ML		N70288 001 AUG 15, 1988
	LACTULOSE			
AA	MY K LABS	10GM/15ML		N71841 001 SEP 22, 1988

SYRUP; ORAL, RECTAL

	CEPHULAC			
AA	MERRELL DOW	10GM/15ML		N17657 001
	CHOLAC			
AA	ALRA LABS	10GM/15ML		N71331 001 JUL 26, 1988
	ENULOSE			
AA	BARRE NATL	10GM/15ML		N71548 001 AUG 15, 1988

LACTULOSE

SYRUP; ORAL, RECTAL

	GENERIC			
AA	MY K LABS	10GM/15ML[M]	N71842 001	SEP 27, 1988
	LACTULOSE			
AA	KALI DUPHAR	10GM/15ML	N17906 001	

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM			
AP	BEN VENUE LABS	EQ 100MG BASE/VIAL[M]	N89717 001	MAR 28, 1988
AP	INTL PHARM	EQ 3MG BASE/ML[M]	N89352 001	JUN 01, 1988
AP		EQ 50MG BASE/VIAL[M]	N89353 001	JUN 01, 1988
AP	LEDERLE LABS	EQ 3MG BASE/ML	N08107 001	
AP		EQ 100MG BASE/VIAL[M]	N08107 004	MAY 23, 1988
AP	QUAD PHARMS	EQ 100MG BASE/VIAL	N89636 001	DEC 24, 1987

LEVOCARNITINE

SOLUTION; ORAL

	CARNITOR			
AA	SIGMA TAU	1GM/10ML[M]	N18948 002	APR 27, 1988
	VITACARN			
AA	KENDALL MCGAW	1GM/10ML	N19257 001	APR 10, 1986

LEVODOPA

CAPSULE; ORAL

	~~LEVODOPA~~			
~~AO~~	~~ICN PHARMS~~	~~100MG~~	~~N16948 003~~	
~~AO~~		~~250MG~~	~~N16948 001~~	
~~AO~~		~~500MG~~	~~N16948 002~~	
	a ICN PHARMS	100MG	N16948 003	
	a	250MG	N16948 001	
	a	500MG	N16948 002	

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	POLOCAINE W/ LEVONORDEFRIN			
AP	ASTRA PHARM PRODS	0.05MG/ML;2%[M]	N89517 001	APR 14, 1988

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL			
AP	ABBOTT LABS	20%[M]	N89362 001	MAY 25, 1988
~~AP~~	~~LEMMON~~	~~1%~~	~~N83627 001~~	
~~AP~~		~~2%~~	~~N83627 002~~	
	a LEMMON	1%	N83627 001	
	a	2%	N83627 002	

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	LINCOCIN			
AP	UPJOHN	EQ 300MG BASE/ML	N50317 001	
	LINCOMYCIN HCL			
AP	QUAD PHARMS	EQ 300MG BASE/ML[M]	N62784 001	MAR 14, 1988

LISINOPRIL

TABLET; ORAL

	PRINIVIL			
AB	MS&D RES LABS	5MG	N19558 001	DEC 29, 1987
AB		10MG	N19558 002	DEC 29, 1987
AB		20MG	N19558 003	DEC 29, 1987
	ZESTRIL			
AB	IMPERIAL CHEM	5MG[M]	N19777 001	MAY 19, 1988
AB		10MG[M]	N19777 002	MAY 19, 1988
AB		20MG[M]	N19777 003	MAY 19, 1988

LOPERAMIDE HYDROCHLORIDE

/SOLUTION;ORAL/
/IMODIUM/
/JANSSEN/PHARMA/ /1MG/5ML/ /N19037/001/ /JUL/31,/1984/

∂ JANSSEN PHARMA	1MG/5ML	N19037 001 JUL 31, 1984	

LORAZEPAM

TABLET; ORAL
LORAZEPAM

AB	CORD LABS	0.5MG*	N71193 001 APR 15, 1988	
AB		1MG*	N71194 001 APR 15, 1988	
AB		2MG*	N71195 001 APR 15, 1988	
AB	WARNER CHILCOTT	1MG*	N71038 001 JAN 12, 1988	
AB		2MG*	N71039 001 JAN 12, 1988	

LOXAPINE SUCCINATE

CAPSULE; ORAL
LOXAPINE SUCCINATE

AB	WATSON LABS	EQ 5MG BASE*	N72204 001 JUN 15, 1988	
AB		EQ 10MG BASE*	N72205 001 JUN 15, 1988	
AB		EQ 25MG BASE*	N72206 001 JUN 15, 1988	
AB		EQ 50MG BASE*	N72062 001 JUN 15, 1988	

LOXITANE

AB	LEDERLE LABS	EQ 5MG BASE*	N17525 001	> ADD >
AB		EQ 10MG BASE*	N17525 002	> ADD >
AB		EQ 25MG BASE*	N17525 003	> ADD >
AB		EQ 50MG BASE*	N17525 004	> ADD >

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL
MAPROTILINE HCL

AB	AM THERPTCS	25MG*	N72129 001 JAN 14, 1988
AB		50MG*	N72130 001 JAN 14, 1988
AB		75MG*	N72131 001 JAN 14, 1988
AB	MYLAN PHARMS	25MG*	N72284 001 OCT 03, 1988
AB		50MG*	N72285 001 OCT 03, 1988
AB		75MG*	N72286 001 OCT 03, 1988
AB	WATSON LABS	25MG*	N72162 001 JUN 01, 1988
AB		50MG*	N72163 001 JUN 01, 1988
AB		75MG*	N72164 001 JUN 01, 1988

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
ANTIVERT

AA	ROERIG	50MG*	N10721 001 JAN 20, 1982

MECLIZINE [illegible]

AA	PAR PHARM	50MG*	N89674 001 MAR 31, 1988

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

AB	CORD LABS	EQ 50MG BASE*	N72262 001 NOV 29, 1988
AB		EQ 100MG BASE*	N72263 001 NOV 29, 1988
AB	PAR PHARM	EQ 50MG BASE*	N72077 001 MAR 10, 1988
AB		EQ 100MG BASE*	N72078 001 MAR 10, 1988
AB	PHARM BASICS	EQ 50MG BASE*	N71007 001 MAR 25, 1988
AB		EQ 100MG BASE*	N71008 001 MAR 25, 1988

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

AB	VITARINE	EQ 50MG BASE[M]	N71710 001 JUN 15, 1988		
AB		EQ 100MG BASE[M]	N71684 001 JUN 15, 1988		

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	VITARINE	250MG[M]	N72179 001 APR 21, 1988		

PONSTEL

AB	PARKE DAVIS PR	250MG	N15034 003		

MEGESTROL ACETATE

TABLET; ORAL

MEGESTROL ACETATE

AB	PAR PHARM	20MG[M]	N72422 001 AUG 08, 1988		
AB		40MG[M]	N72423 001 AUG 08, 1988		

MEPENZOLATE BROMIDE

~~SOLUTION; ORAL~~

~~CANTIL~~

	~~MERRELL DOW~~	~~25MG/5ML~~	~~N10679 004~~		
	@ MERRELL DOW	25MG/5ML	N10679 004		

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

~~AA~~	~~MALLARD~~	~~400MG~~	~~N15072 002~~		
	@ MALLARD	400MG	N15072 002		
~~AA~~	~~PHARM BASICS~~	~~200MG~~	~~N87825 001~~ ~~MAR 18, 1982~~		
~~AA~~		~~400MG~~	~~N87826 001~~ ~~MAR 18, 1982~~		
	@ PHARM BASICS	200MG	N87825 001 MAR 18, 1982		
	@	400MG	N87826 001 MAR 18, 1982		

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

				> DLT > ~~AA~~	~~STANLABS PHARM~~ ~~400MG~~ ~~N14474 004~~
				> ADD >	@ STANLABS PHARM 400MG N14474 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/50M-21

AB	SEARLE PHARMS	0.05MG;1MG[M]	N71539 001 APR 12, 1988		

NORETHINDRONE AND MESTRANOL

AB	WATSON LABS	0.05MG;1MG[M]	N70758 001 JUL 01, 1988		

TABLET; ORAL-28

NORETHIN 1/50M-28

AB	SEARLE PHARMS	0.05MG;1MG[M]	N71540 001 APR 12, 1988		

NORETHINDRONE AND MESTRANOL

AB	WATSON LABS	0.05MG;1MG[M]	N70759 001 JUL 01, 1988		

MESTRANOL; NORETHYNODREL

TABLET; ORAL-20

ENOVID

~~AA~~	~~SEARLE~~	~~0.075MG;5MG~~	~~N10976 004~~		
	@ SEARLE	0.075MG;5MG	N10976 004		

~~ENOVID-E~~

~~AA~~	~~SEARLE~~	~~0.1MG;2.5MG~~	~~N10976 006~~		
	@ SEARLE	0.1MG;2.5MG	N10976 006		

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

AN	BOEHR INGEL	0.4%	N18761 002 OCT 10, 1986		

DEY-DOSE

AN	DEY LABS	5%	N70805 001 AUG 17, 1987		

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	DEY-LUTE			
AN	DEY LABS	0.4%		N71786 001 AUG 05, 1988
AN		0.6%		N70804 001 AUG 17, 1987
		0.33%		N71806 001 AUG 05, 1988
		0.5%		N71805 001 AUG 05, 1988
	METAPROTERENOL SULFATE			
AN	ARMOUR PHARM	0.4%		N71275 001 JUL 27, 1988
AN		0.6%		N71018 001 JUL 27, 1988
/AN/	/DEY/LABS/	/0.6%/		/N70804/001/ /AUG/17,/1987/
/AN/		/5%/		/N70805/001/ /AUG/17,/1987/
AN	MY K LABS	5%		N72190 001 JUN 07, 1988
AN	PACO RES	0.4%		N71855 001 JUL 14, 1988
AN		0.6%		N71726 001 JUL 14, 1988

SYRUP; ORAL

>DLT>	/METSOL/			
>DLT>/AA/	/MURO/PHARM/	/10MG/5ML/		/N72023/001/ /SEP/15,/1988/
>DLT>				
>ADD>	PROMETA			
>ADD> AA	MURO PHARM	10MG/5ML		N72023 001 SEP 15, 1988
>ADD>				

TABLET; ORAL

	ALUPENT			
AB	BOEHR INGEL	10MG		N15874 002
AB		20MG		N15874 001
	METAPROTERENOL SULFATE			
AB	AM THERPTCS	10MG		N72054 001 JUN 23, 1988
AB		20MG		N72055 001 JUN 23, 1988
AB	PAR PHARM	10MG		N72024 001 JUN 28, 1988
AB		20MG		N72025 001 JUN 28, 1988
AB	PHARM BASICS	10MG		N71013 001 JAN 25, 1988
AB		20MG		N71014 001 JAN 25, 1988

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

	METHADONE			
AA	MALLINCKRODT	10MG/ML		N17116 002
	METHADONE HCL INTENSOL			
AA	ROXANE LABS	10MG/ML		N89897 001 SEP 06, 1988

METHIXENE HYOROCHLORIDE

/TABLET;/ORAL/

	/TEST/			
	/DORSEY/LABS/	/1MG/		/N13420/001/
	∂ DORSEY LABS	1MG		N13420 001

METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL			
/AA/	/BARR/LABS/	/500MG/		/N84488/001/
	∂ BARR LABS	500MG		N84488 001

/METHOTREXATE/

/TABLET;/ORAL/

	/METHOTREXATE/			
	/LEDERLE/LABS/	/2.5MG/		/N08085/002/

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	METHOTREXATE			
	LEDERLE LABS	EQ 1GM BASE/VIAL		N11719 009 APR 07, 1988
	METHOTREXATE SODIUM			
AP	PHARMACHEMIE	EQ 25MG BASE/ML		N89158 001 JUL 08, 1988

TABLET; ORAL

	METHOTREXATE			
	LEDERLE LABS	EQ 2.5MG BASE		N08085 002

METHOXSALEN

CAPSULE; ORAL

	/OXSORALEN/			
/BP/	/ELDER/PHARMS/	/10MG/		/N09646/001/

METHOXSALEN

CAPSULE; ORAL
8-MOP

	ELDER PHARMS	10MG	N09048 001

METHYCLOTHIAZIDE

TABLET; ORAL
METHYCLOTHIAZIDE

AB	CORD LABS	2.5MG	N89835 001 AUG 18, 1988
AB		5MG	N89837 001 AUG 18, 1988

METHYLDOPA

TABLET; ORAL
METHYLDOPA

AB	CORD LABS	125MG	N71700 001 MAR 02, 1988
AB	HALSEY DRUG	125MG	N71751 001 MAR 28, 1988
AB		250MG	N71752 001 MAR 28, 1988
AB		500MG	N71753 001 MAR 28, 1988
AB	SIDMAK LABS	125MG	N72126 001 JUL 07, 1988
AB		250MG	N72127 001 JUL 07, 1988
AB		500MG	N72128 001 JUL 07, 1988

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CONTROLLED RELEASE; ORAL
METHYLPHENIDATE HCL

AB	MD PHARM	20MG	N89601 001 JUN 01, 1988

RITALIN-SR

AB	CIBA PHARM	20MG	N18029 001 MAR 30, 1982

METHYLPREDNISOLONE

TABLET; ORAL
MEDROL

AB	UPJOHN	24MG	N11153 005
AB		32MG	N11153 006

METHYLPREDNISOLONE

AB	HEATHER DRUG	4MG	N85650 001
/BP/		/4MG/	/N85650/001/
AB	PAR PHARM	16MG	N89207 001 APR 25, 1988
AB		24MG	N89208 001 APR 25, 1988
AB		32MG	N89209 001 APR 25, 1988

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

>ADD> AP	DUPONT CRI CARE	EQ 10MG BASE/2ML	N70847 001 NOV 07, 1988
AP	MAURRY BIOL	EQ 10MG BASE/2ML	N70892 001 AUG 26, 1988

SYRUP; ORAL
METOCLOPRAMIDE HCL

AA	BARRE NATL	EQ 5MG BASE/5ML	N71340 001 AUG 18, 1988

TABLET; ORAL
CLOPRA

AB	QUANTUM PHARMCS	EQ 5MG BASE	N72384 001 JUN 02, 1988

METOCLOPRAMIDE HCL

AB	SIDMAK LABS	EQ 10MG BASE	N71250 001 FEB 03, 1988

REGLAN

AB	ROBINS	EQ 5MG BASE	N17854 002 MAY 05, 1987

METOCURINE IODIDE

INJECTABLE; INJECTION
METOCURINE IODIDE

AP	QUAD PHARMS	2MG/ML	N89443 001 JUN 01, 1988

METUBINE IODIDE

AP	LILLY	2MG/ML	N06632 003

METOLAZONE

TABLET; ORAL

/MICROX/
/PENNMALT/ /0.5MG/ /N19532/001/ /OCT/30/1987/

MYKROX
FISONS 0.5MG N19532 001 OCT 30, 1987

METRONIDAZOLE

> ADD > GEL; TOPICAL
> ADD > METROGEL
> ADD > CURATEK PHARMS 0.75%[RX] N19737 001 NOV 22, 1988
> ADD >

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
MEZLIN
MILES PHARM EQ 20GM BASE/VIAL[RX] N50549 005 MAR 02, 1988
EQ 20GM BASE/VIAL[RX] N62372 004 MAR 02, 1988

MINOXIDIL

SOLUTION; TOPICAL
ROGAINE
UPJOHN 2%[RX] N19501 001 AUG 17, 1988

TABLET; ORAL
MINODYL
AB QUANTUM PHARMCS 2.5MG[RX] N72153 001 JUL 13, 1988

MINOXIDIL
> ADD > AB PAR PHARM 2.5MG[RX] N71826 001 NOV 14, 1988
> ADD >
> ADD > AB 10MG[RX] N71839 001 NOV 14, 1988
> ADD >

MITOMYCIN

INJECTABLE; INJECTION
MUTAMYCIN
BRISTOL MYERS 40MG/VIAL[RX] N62336 003 MAR 10, 1988

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE
AP ABBOTT LABS 0.5MG/ML[RX] N71849 001 MAY 11, 1988
AP 1MG/ML[RX] N71850 001 MAY 11, 1988

TABLET, CONTROLLED RELEASE; ORAL
MS CONTIN
PURDUE FRDRK 60MG[RX] N19516 002 APR 08, 1988

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM
AP MARSAM PHARMS EQ 500MG BASE/VIAL[RX] N62844 001 OCT 26, 1988
AP EQ 1GM BASE/VIAL[RX] N62844 002 OCT 26, 1988
AP EQ 2GM BASE/VIAL[RX] N62844 004 OCT 26, 1988
AP EQ 4GM BASE/VIAL[RX] N62844 005 OCT 26, 1988
AP EQ 10GM BASE/VIAL[RX] N63008 001 SEP 29, 1988
EQ 1.5GM BASE/VIAL[RX] N62844 003 OCT 26, 1988

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN
HERBERT LABS 1%[RX] N19599 001 FEB 29, 1988

NALIDIXIC ACID

TABLET; ORAL
NALIDIXIC ACID
AB DANBURY PHARMA 250MG[RX] N71936 001 JUN 29, 1988 : JUN 28, 1988
AB 500MG[RX] N72061 001 JUN 29, 1988 : JUN 28, 1988
AB 1GM[RX] N71919 001 JUN 29, 1988 : JUN 28, 1988

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP	DUPONT CRI CARE	0.4MG/ML	N71083 001 JUL 28, 1988
AP		1MG/ML	N71084 001 JUL 28, 1988
AP		1MG/ML	N71311 001 JUL 28, 1988
AP	ELKINS SINN	0.02MG/ML	N71272 001 MAY 24, 1988
AP		1MG/ML	N71273 001 MAY 24, 1988
AP		1MG/ML	N71274 001 MAY 24, 1988
AP		1MG/ML	N71287 001 MAY 24, 1988
AP	INTL MEDTN SYS	1MG/ML	N72076 001 MAR 24, 1988
AP		1MG/ML	N72115 001 APR 27, 1988
AP	MARSAM PHARMS	0.4MG/ML	N71811 001 JUL 19, 1988

NITROFURANTOIN

/CAPSULE;ORAL/
/NITROFURANTOIN/
/BOLAR PHARM/

ə BOLAR PHARM	/50MG/ 50MG	/N84326/001/ N84326 001
ə	/100MG/ 100MG	/N84326/002/ N84326 002

TABLET; ORAL
NITROFURANTOIN
/BOLAR PHARM/

/BP/ ə BOLAR PHARM	/100MG/ 100MG	/N80447/002/ N80447 002

NITROFURANTOIN SODIUM

/INJECTABLE;INJECTION/
/IVADANTIN/
/NORWICH EATON/

ə NORWICH EATON	/EQ 100MG BASE/VIAL/ EQ 100MG BASE/VIAL	/N12402/001/ N12402 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACRODANTIN

AB	NORWICH EATON	50MG	N16620 001
AB		100MG	N16620 002

NITROFURANTOIN MACROCRYSTALLINE

AB	BOLAR PHARM	50MG	N70248 001 JUN 24, 1988
AB		100MG	N70249 001 JUN 24, 1988

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

AP	LUITPOLD PHARMS	5MG/ML	N71492 001 MAY 24, 1988
AP		5MG/ML	N72034 001 MAY 24, 1988

OINTMENT; TOPICAL
NITROGLYCERIN

ALTANA	2%	N87355 001 JUL 08, 1988

NIZATIDINE

CAPSULE; ORAL
AXID

LILLY	150MG	N19508 001 APR 12, 1988
	300MG	N19508 002 APR 12, 1988

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
AVENTYL HCL

BD	LILLY	EQ 10MG BASE	N14684 001
BD		EQ 25MG BASE	N14684 002
/BP/		/EQ 10MG BASE/	/N14684/001/
/BP/		/EQ 25MG BASE/	/N14684/002/

PAMELOR

BD	SANDOZ PHARMS	EQ 10MG BASE	N18013 001
BD		EQ 25MG BASE	N18013 002
/BP/		/EQ 10MG BASE/	/N18013/001/
/BP/		/EQ 25MG BASE/	/N18013/002/

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	NASKA PHARMA	100,000 UNITS/GM	N62949 001	JUN 13, 1988

SUSPENSION; ORAL

NYSTATIN

AA	THAMES PHARMA	100,000 UNITS/ML	N62876 001	FEB 29, 1988

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

SANDOSTATIN

	SANDOZ PHARMS	EQ 0.05MG BASE/ML	N19667 001	OCT 21, 1988
		EQ 0.1MG BASE/ML	N19667 002	OCT 21, 1988
		EQ 0.5MG BASE/ML	N19667 003	OCT 21, 1988

OXACILLIN SODIUM

INJECTABLE; INJECTION

BACTOCILL

AP	BEECHAM LABS	EQ 10GM BASE/VIAL	N61334 010	

OXACILLIN SODIUM

AP	MARSAM PHARMS	EQ 250MG BASE/VIAL	N62856 001	OCT 26, 1988
AP		EQ 500MG BASE/VIAL	N62856 002	OCT 26, 1988
AP		EQ 1GM BASE/VIAL	N62856 003	OCT 26, 1988
AP		EQ 2GM BASE/VIAL	N62856 004	OCT 26, 1988
AP		EQ 4GM BASE/VIAL	N62856 005	OCT 26, 1988
AP		EQ 10GM BASE/VIAL	N62984 001	SEP 29, 1988

PROSTAPHLIN

AP	BRISTOL LABS	EQ 250MG BASE/VIAL	N50195 001	
AP		EQ 250MG BASE/VIAL	N61490 001	

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AB	AM THERPTCS	10MG	N71955 001		MAR 03, 1988
AB		15MG	N71956 001		MAR 03, 1988
AB		30MG	N71957 001		MAR 03, 1988
> ADD > AB	BARR LABS	10MG	N70957 001		AUG 10, 1987
> ADD > AB		15MG	N71025 001		AUG 10, 1987
AB		30MG	N71026 001		AUG 10, 1987
> DLT > /BP/		/10MG/	/N70957/001/		/AUG/10,/1987/
> DLT > /BP/		/15MG/	/N71025/001/		/AUG/10,/1987/
/BP/		/30MG/	/N71026/001/		/AUG/10,/1987/
AB	CHELSEA LABS	10MG	N71661 001		MAR 02, 1988
AB		15MG	N71662 001		MAR 02, 1988
AB		30MG	N71663 001		MAR 02, 1988
AB	CORD LABS	10MG	N71813 001		APR 19, 1988
AB		15MG	N71756 001		APR 19, 1988
AB		30MG	N71814 001		APR 19, 1988
/BP/	/MYLAN/PHARMS/	/10MG/	/N71713/001/		/OCT/20,/1987/
/BP/		/15MG/	/N71714/001/		/OCT/20,/1987/
/BP/		/30MG/	/N71715/001/		/OCT/20,/1987/
a	MYLAN PHARMS	10MG	N71713 001		OCT 20, 1987
a		15MG	N71714 001		OCT 20, 1987
a		30MG	N71715 001		OCT 20, 1987
AB	PUREPAC PHARM	10MG	N72251 001		APR 14, 1988
AB		15MG	N72252 001		APR 14, 1988
AB		30MG	N72253 001		APR 14, 1988

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AB	ZENITH LABS	10MG	N70943 001 AUG 03, 1987
AB		15MG	N70944 001 AUG 03, 1987
AB		30MG	N70945 001 AUG 03, 1987
/BP/		/10MG/	/N70943/001/ /AUG 03, 1987/
/BP/		/15MG/	/N70944/001/ /AUG 03, 1987/
/BP/		/30MG/	/N70945/001/ /AUG 03, 1987/

SERAX

AB	WYETH	10MG	N15539 002
AB		15MG	N15539 004
AB		30MG	N15539 006
/BP/		/10MG/	/N15539/002/
/BP/		/15MG/	/N15539/004/
/BP/		/30MG/	/N15539/006/

ZAMOPAM

AB	QUANTUM PHARMCS	10MG*	N70650 001 MAR 01, 1988
AB		15MG*	N70640 001 MAR 01, 1988
AB		30MG*	N70641 001 MAR 01, 1988

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

AB	MARION LABS	5MG*	N17577 001

OXYBUTYNIN CHLORIDE

AB	PHARM BASICS	5MG*	N70746 001 MAR 10, 1988
>ADD> AB	SIDMAK LABS	5MG*	N71655 001 NOV 14, 1988

>ADD>

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

DARICON

/BEECHAM/LABS/	/10MG/	/N11612/001/
PFIZER LABS	10MG	N11612 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

OXYTETRACYCLINE HCL

/AA/	/PUREPAC PHARM/	/EQ 250MG BASE/	/N60634/001/
∂ PUREPAC PHARM		EQ 250MG BASE	N60634 001

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM

AP	ELKINS SINN	1MG/ML*	N72058 001 MAR 23, 1988
AP		2MG/ML*	N72059 001 MAR 23, 1988
AP		2MG/ML*	N72060 001 MAR 23, 1988

PANCURONIUM BROMIDE

AP	ASTRA PHARM PRODS	1MG/ML*	N72210 001 MAR 31, 1988
AP		2MG/ML*	N72211 001 MAR 31, 1988
AP		2MG/ML*	N72212 001 MAR 31, 1988
AP		2MG/ML*	N72213 001 MAR 31, 1988
AP	QUAD PHARMS	1MG/ML*	N72209 001 JUN 03, 1988
AP		2MG/ML*	N72208 001 JUN 03, 1988

PAVULON

AP	ORGANON	1MG/ML*	N17015 002
AP		2MG/ML*	N17015 001

PARAMETHADIONE

/CONCENTRATE;ORAL/

/PARADIONE/

/AA/	/ABBOTT LABS/	/300MG/ML/	/N06800/002/

SOLUTION; ORAL

PARADIONE

AA	ABBOTT LABS	300MG/ML	N06800 002

PENICILLAMINE

CAPSULE; ORAL
CUPRIMINE

	MS&D	125MG	N19853 002
		250MG	N19853 001

TABLET; ORAL
DEPEN 250

	WALLACE LABS	250MG	N19854 001

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM

AP	MARSAM PHARMS	1,000,000 UNITS/VIAL	N62991 001 SEP 13, 1988
AP		5,000,000 UNITS/VIAL	N62991 002 SEP 13, 1988
AP		10,000,000 UNITS/VIAL	N62991 003 SEP 13, 1988
AP		20,000,000 UNITS/VIAL	N62991 004 SEP 13, 1988
AP	SQUIBB	10,000,000 UNITS/VIAL	N60362 004

POWDER FOR RECONSTITUTION; ORAL
PENICILLIN G POTASSIUM

	ə PUREPAC PHARM	400,000 UNITS/5ML	N61740 002

TABLET; ORAL
PENICILLIN G POTASSIUM

	ə PUREPAC PHARM	250,000 UNITS	N61588 002
	ə	400,000 UNITS	N61588 003

PENICILLIN G SODIUM

INJECTABLE; INJECTION
PENICILLIN G SODIUM

	MARSAM PHARMS	5,000,000 UNITS/VIAL	N63014 001 SEP 13, 1988
	ə SQUIBB SPA	5,000,000 UNITS/VIAL	N61935 001

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
PENICILLIN V POTASSIUM

	ə PUREPAC PHARM	EQ 250MG BASE/5ML	N61758 002

TABLET; ORAL
PENICILLIN V POTASSIUM

> ADD > AB	CLONMEL CHEMS	EQ 250MG BASE	N62936 001 > ADD > NOV 25, 1988
> ADD > AB		EQ 500MG BASE	N62935 001 > ADD > NOV 23, 1988
	ə PUREPAC PHARM	EQ 250MG BASE	N61571 002
	ə	EQ 500MG BASE	N61571 003

PERPHENAZINE

SYRUP; ORAL
TRILAFON

	ə SCHERING	2MG/5ML	N11294 002

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

	ə BARR LABS	35MG	N83644 001
	ə	35MG	N83684 001
	ə	35MG	N83686 001
	ə	35MG	N83687 001
	ə	35MG	N84831 001
	ə	35MG	N84834 001
	ə	35MG	N84835 001

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL
PRELUDIN

	ə BOEHR INGEL	25MG	N10460 005

PHENTERMINE RESIN COMPLEX

CAPSULE, CONTROLLED RELEASE; ORAL

	IONAMIN-30			
AB	PENNWALT	EQ 30MG BASE‡		N11613 002
	PHENTERMINE RESIN 30			
AB	QUANTUM PHARMCS	EQ 30MG BASE‡		N89120 001 FEB 04, 1988

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHENERGAN VC			
AA	WYETH/AYERST/LABS	5MG/5ML;6.5MG/5ML		N86664/001 APR 02, 1984

PIPERACETAZINE

TABLET; ORAL

	QUIDE			
	DON PHARMS	10MG		N13615 001
	∂ DON PHARMS	10MG		N13615 001
		25MG		N13615 002
	∂	25MG		N13615 002

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

PONDER FOR RECONSTITUTION; ORAL

> ADD >	E-Z-EM PREP LYTE			
> ADD > AA	E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT‡		N71278 001 NOV 21, 1988
> ADD >	GOLYTELY			
> ADD > AA	BRAINTREE LABS	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT‡		N19011 001 JUL 13, 1984

SOLUTION; ORAL

	OCL			
	ABBOTT/LABS	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML; 1.29GM/100ML		N19284 001 APR 30, 1986
	ABBOTT LABS	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML; 1.29GM/100ML		N19284 001 APR 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

PONDER FOR RECONSTITUTION; ORAL

	COLONLYTE			
AA	DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET‡		N71320 001 APR 20, 1988
	COLOVAGE			
AA	DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET‡		N71320 001 APR 20, 1988
	COLYTE			
AA	REED & CARNRICK	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET		N18983 004 OCT 26, 1984

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

	POLYTRIM			
	BURROUGHS WELLC	10,000 UNITS/ML; EQ 1MG BASE/ML‡		N50567 001 OCT 20, 1988

POTASSIUM AMINOSALICYLATE

POWDER; ORAL

	POTASSIUM AMINOSALICYLATE			
	HEXCEL CHEM	100%		N80098 001
	∂ HEXCEL CHEM	100%		N80098 001

POTASSIUM CHLORIDE

CAPSULE, CONTROLLED RELEASE; ORAL

	MICRO-K 10			
AB	ROBINS	10MEQ		N18238 002 MAY 14, 1984
BC		10MEQ		N18238 002 MAY 14, 1984
	POTASSIUM CHLORIDE			
AB	KV PHARM	10MEQ		N70980 001 FEB 17, 1987
BC		10MEQ		N70980 001 FEB 17, 1987

POTASSIUM CHLORIDE

GRANULE FOR RECONSTITUTION, CR; ORAL
MICRO-K LS

	ROBINS	20MEQ/PACKET	N19561 003 AUG 26, 1988	>ADD> >ADD>

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	STERIS LABS	2MEQ/ML	N89163 001 MAR 10, 1988	

TABLET, CONTROLLED RELEASE; ORAL
POTASSIUM CHLORIDE

BC	ABBOTT LABS	8MEQ	N18279 002 AUG 01, 1988	

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	149MG/100ML; 900MG/100ML	N19686 001 OCT 17, 1988	

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	298MG/100ML; 900MG/100ML	N19686 002 OCT 17, 1988	

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL
POTASSIUM CITRATE

	UNIV TEXAS	10MEQ/PACKET	N19647 002 OCT 13, 1988	
		20MEQ/PACKET	N19647 001 OCT 13, 1988	

TABLET, CONTROLLED RELEASE; ORAL
POTASSIUM CITRATE

	UNIV TEXAS	5MEQ	N19071 001 AUG 30, 1985	
	/UROCIT-K/ /UNIV/TEXAS/	/5MEQ/	/N19071/001/ /AUG/30,/1985/	

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION
PRALIDOXIME CHLORIDE

AP	QUAD PHARMS	1GM/VIAL	N72224 001 NOV 23, 1988	

PROTOPAM CHLORIDE

AP	WYETH AYERST LABS	1GM/VIAL	N14134 001	>ADD>

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
MINIPRESS

AB	PFIZER LABS	1MG	N17442 002	
AB		2MG	N17442 003	
AB		5MG	N17442 001	

PRAZOSIN HCL

AB	ZENITH LABS	1MG	N71994 001 MAY 16, 1989 : SEP 12, 1988	
AB		2MG	N71995 001 MAY 16, 1989 : SEP 12, 1988	
AB		5MG	N71745 001 MAY 16, 1989 : SEP 12, 1988	

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

/BX/	/BARR/LABS/	/5MG/	/N84426/002/
	∂ BARR LABS	5MG	N84426 002
/BX/	/STERANE/ /PFIPHARMECS/	/5MG/	/N09996/001/
	∂ PFIZER LABS	5MG	N09996 001

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
VASOCIDIN

	IOLAB PHARMS	EQ 0.23% PHOSPHATE;10%	N18988 001 AUG 26, 1988

PREDNISONE

SOLUTION; ORAL
PREDNISONE

AA	MY K LABS	5MG/5ML	N89726 001 AUG 02, 1988
AA	ROXANE LABS	5MG/5ML	N88703 001 NOV 08, 1984

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	SUPERPHARM	5MG	N88865 001 OCT 25, 1984
AB		10MG	N88866 001 OCT 25, 1984
AB		20MG	N88867 001
/BX/		/5MG/	
/BX/		/10MG/	
/BX/		/20MG/	

PROBUCOL

TABLET; ORAL
LORELCO

	MERRELL DON	500MG*	N17535 002 JUL 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL
PROCAINAMIDE HCL

/AA/	/LEDERLE/LABS/	/250MG/	/N86942/001/
/AA/		/375MG/	/N86952/001/
/AA/		/500MG/	/N86943/001/
	ə LEDERLE LABS	250MG	N86942 001
	ə	375MG	N86952 001
	ə	500MG	N86943 001

INJECTABLE; INJECTION
PROCAINAMIDE HCL

AP	MARNER CHILCOTT	100MG/ML*	N89528 001 MAY 03, 1988
AP		500MG/ML*	N89529 001 MAY 03, 1988

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	ELKINS SINN	EQ 5MG BASE/ML*	N89523 001 MAY 03, 1988

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	QUAD PHARMS	EQ 5MG BASE/ML*	N89637 001 FEB 01, 1988
AP		EQ 5MG BASE/ML*	N89638 001 FEB 01, 1988
AP	STERLING DRUG	EQ 5MG BASE/ML*	N89703 001 APR 07, 1988

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	MARSAM PHARMS	25MG/ML*	N89463 001 MAY 02, 1988
AP		50MG/ML*	N89477 001 MAY 02, 1988

TABLET; ORAL
PROMETHAZINE HCL

/BP/	/BARR/LABS/	/12.5MG/	/N84555/001/
/BP/		/25MG/	/N84554/001/
/BP/		/50MG/	/N84557/001/
	ə BARR LABS	12.5MG	N84555 001
	ə	25MG	N84554 001
	ə	50MG	N84557 001

PROPIOLACTONE

SOLUTION; IRRIGATION
BETAPRONE

	FOREST LABS	N/A*	N11657 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

/AA/	/BANMAX/PHARMS/	/65MG/	/N83184/001/
	ə BANMAX PHARMS	65MG	N83184 001
/AA/	/BARR/LABS/	/65MG/	/N83186/001/
	ə BARR LABS	65MG	N83186 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	INVAMED	10MG	N71658 001	JUL 05, 1988
AB		20MG	N71687 001	JUL 05, 1988
AB		40MG	N71688 001	JUL 05, 1988
AB		60MG	N72197 001	JUL 05, 1988
AB		80MG	N71689 001	JUL 05, 1988
AB		90MG	N72198 001	JUL 05, 1988
AB	LEDERLE LABS	10MG	N72117 001	JUN 23, 1988
AB		20MG	N72118 001	JUN 23, 1988
AB		40MG	N72119 001	JUN 23, 1988
AB		80MG	N72120 001	JUN 23, 1988
/AA/	/LEMMON/	/10MG/	/N62354/001/	/OCT/07,/1987/
	ə LEMMON	10MG	N70232 001	OCT 07, 1987
/AA/	/PARKE/DAVIS/	/10MG/	/N70438/001/	/SEP/15,/1986/
AB	SIDMAK LABS	10MG	N71972 001	APR 06, 1988
AB		20MG	N71973 001	APR 06, 1988
AB		40MG	N71974 001	APR 06, 1988
AB		60MG	N71975 001	APR 06, 1988
AB		80MG	N71976 001	APR 06, 1988
AB		90MG	N71977 001	APR 06, 1988
AB	SUPERPHARM	10MG	N71515 001	JUN 08, 1988
AB		20MG	N71516 001	JUN 08, 1988
AB		40MG	N71517 001	JUN 08, 1988
AB		80MG	N71518 001	JUN 08, 1988
AB	WARNER CHILCOTT	10MG	N70438 001	SEP 15, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	ZENITH LABS	10MG	N72063 001	JUL 29, 1988
AB		20MG	N72066 001	JUL 29, 1988
AB		40MG	N72067 001	JUL 29, 1988
AB		60MG	N72068 001	JUL 29, 1988
AB		80MG	N72069 001	JUL 29, 1988

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

/A1/	/UPJOHN/	/50MG/VIAL/	/N07413/001/	
/A2/		/250MG/VIAL/	/N07413/002/	/AUG/02,/1984/
	ə UPJOHN	50MG/VIAL	N07413 001	
	ə	250MG/VIAL	N07413 002	AUG 02, 1984

QUINESTROL

/TABLET;/ORAL/			
/ESTROVIS/			
/PARKE/DAVIS/	/0.1MG/	/N16768/002/	
ə PARKE DAVIS	0.1MG	N16768 002	
	/0.2MG/	/N16768/003/	
ə	0.2MG	N16768 003	

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB	CORD LABS	300MG	N89839 001	SEP 29, 1988

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUVAL

BP	VALE CHEM	50MG	N09108 002
BP		100MG	N09108 004

RESERPINE

TABLET; ORAL
RESERPINE

Ø BARR LABS		0.25MG	N80721 002

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
TRICHLORMETHIAZIDE W/RESERPINE

Ø BOLAR PHARM		0.1MG;4MG	N85248 001

SECOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM SECOBARBITAL

Ø BARR LABS		100MG	N84225 001

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS

	LAFAYETTE	460MG/GM;420MG/GM	N18509 001 AUG 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	900MG/100ML	N19635 002 MAR 09, 1988

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT LABS	450MG/100ML	N19759 001 JUN 08, 1988
AP	KENDALL MCGAW	450MG/100ML	N19635 001 MAR 09, 1988

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	9MG/ML	N19217 001 JUL 13, 1984

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	3GM/100ML	N19635 003 MAR 09, 1988
AP	TRAVENOL LABS	3GM/100ML	N19022 001 NOV 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML	N19635 004 MAR 09, 1988
AP	TRAVENOL LABS	5GM/100ML	N19022 002 NOV 01, 1983

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131

Ø MALLINCKRODT		0.8-100MCI	N16515 002

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS

	ABBOTT LABS	25MG/ML	N71961 001 AUG 01, 1988

SODIUM SUCCINATE

INJECTABLE; INJECTION
SODIUM SUCCINATE

Ø ELKINS SINN		30%	N80516 001

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

/AA/	/LEDERLE/LABS/	/25MG/	/N07634/001/
	∂ LEDERLE LABS	25MG	N07634 001

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

AT	STERIS LABS	10%	N89560 001 OCT 18, 1988

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

/AA/	/BARR/LABS/	/500MG/	/N71189/001/ /JUL 25, 1983/
	∂ BARR LABS	500MG	N87189 001 JUL 25, 1983

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

TRIMETH/SULFA

AB	NASKA PHARMA	200MG/5ML;40MG/5ML	N72289 001 MAY 23, 1988
AB		200MG/5ML;40MG/5ML	N72398 001 MAY 23, 1988
AB		200MG/5ML;40MG/5ML	N72399 001 MAY 23, 1988

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

/AA/	/BARR/LABS/	/500MG/	/N84031/001/
	∂ BARR LABS	500MG	N84031 001
/AA/	/LEDERLE/LABS/	/500MG/	/N87649/001/
	∂ LEDERLE LABS	500MG	N87649 001

SULINDAC

TABLET; ORAL

CLINORIL

AB	MSD	150MG	N17911 001
AB		200MG	N17911 002

SULINDAC

AB	AM THERPTCS	150MG	N72171 001 APR 03, 1990 : MAY 23, 1988
AB		200MG	N72172 001 APR 03, 1990 : MAY 23, 1988
AB	DANBURY PHARMA	150MG	N71891 001 APR 03, 1990 : MAR 03, 1988
AB		200MG	N71795 001 APR 03, 1990 : MAR 03, 1988

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION

/DOT STANDUS DIPHOSPHONATE/

/AA/	/MEDI PHYSICS/	/N/A/	/N17667/001/
	∂ MEDI PHYSICS	N/A	N17667 001

/OSTEOSCAN/

/AA/	/MALLINCKRODT/	/N/A/	/N17454/001/
	OSTEOSCAN MALLINCKRODT	N/A	N17454 001

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	CORD LABS	15MG	N71427 001 JAN 12, 1988
AB		30MG	N71428 001 JAN 12, 1988
AB	DURAMED PHARMS	15MG	N71708 001 SEP 29, 1988
AB		30MG	N71709 001 SEP 29, 1988

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

HYTRIN

/3/	/ABBOTT/LABS/	/10MG/	/N19057/004/ /AUG 07, 1987/
	ABBOTT LABS	10MG	N19057 004 AUG 07, 1987

TERCONAZOLE

SUPPOSITORY; VAGINAL

	TERAZOL 3		
	ORTHO PHARM	80MG	N19641 001 MAY 24, 1988

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

	TESTOSTERONE CYPIONATE		
AQ	QUAD PHARMS	100MG/ML	N89326 001 OCT 28, 1988
AQ		200MG/ML	N89327 001 OCT 28, 1988

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL		
AB	LABROS ATRAL	250MG	N62752 001 AUG 12, 1988
AB		500MG	N62752 002 AUG 12, 1988
AB	VITARINE	250MG	N61471 001

THEOPHYLLINE

ELIXIR; ORAL

	THEOPHYLLINE		
AA	NASKA PHARMA	80MG/15ML	N89223 001 MAY 27, 1988
AA	THAMES PHARMA	80MG/15ML	N89626 001 OCT 28, 1988

INJECTABLE; INJECTION

	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER		
AP	TRAVENOL LABS	320MG/100ML	N18649 006 NOV 13, 1985
	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER		
AP	ABBOTT LABS	320MG/100ML	N19211 006 JAN 20, 1988

TABLET, CONTROLLED RELEASE; ORAL

	THEOLAIR-SR		
BC	RIKER LABS	250MG	N86363 002 JUL 16, 1987
		/250MG/	/N86363/002/ /JUL/16/1987/

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

	THIORIDAZINE HCL		
AB	MUTUAL PHARM	100MG	N89953 001 OCT 07, 1988
AB	PAR PHARM	150MG	N89764 001 FEB 09, 1988
AB		200MG	N89765 001 FEB 09, 1988
AB	ROXANE LABS	25MG	N88664 001 MAR 15, 1984

TIOCONAZOLE

	/OINTMENT;VAGINAL/ /VAGISTAT/ /ROERIG/	/6.5%/	/N19355/001/ /DEC/30/1986/
	∂ ROERIG	6.5%	N19355 001 DEC 30, 1986

TIOPRONIN

TABLET; ORAL

	TIOPRONIN		
	UNIV TEXAS	100MG	N19569 001 AUG 11, 1988

TOLAZAMIDE

TABLET; ORAL

	TOLAZAMIDE		
AB	PHARM BASICS	100MG	N71355 001 JAN 11, 1988

TOLBUTAMIDE

TABLET; ORAL

	TOLBUTAMIDE		
/AB/	/BANMAX PHARMS/	/500MG/	/N86141/001/
	∂ BANMAX PHARMS	500MG	N86141 001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

AB	MEAD JOHNSON	150MG	N18207 003 MAR 25, 1985

TRAZODONE HCL

AB	PUREPAC PHARM	50MG	N71636 001 APR 18, 1988
AB		100MG	N71514 001 APR 18, 1988
AB	SIDMAK LABS	50MG	N71523 001 DEC 11, 1987
AB		100MG	N71524 001 DEC 11, 1987
/AB/	/TRAZON-100/ /SIDMAK/LABS/	/100MG/	/N71524/001/ /DEC/11,/1987/

TRAZON-150

AB	SIDMAK LABS	150MG	N71525 001 MAR 09, 1988
/AB/	/TRAZON-50/ /SIDMAK/LABS/	/50MG/	/N71523/001/ /DEC/11,/1987/

† SEE SECTION 1.4 OF INTRODUCTION

TRETINOIN

CREAM; TOPICAL

RETIN-A

	ORTHO PHARM	0.025%	N19049 001 SEP 16, 1988

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE

/BP/	/BARR/LABS/	/2MG/	[illegible]
/BP/		/2MG/	
/BP/		/4MG/	
/BP/		/4MG/	
/BP/		/8MG/	
/BP/		/8MG/	
	a BARR LABS	2MG	[illegible]
	a	2MG	N84318 001
	a	4MG	N84267 001
	a	4MG	N84319 001
	a	8MG	N84268 001
	a	8MG	N84320 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

FLUTEX

AT	SYOSSET LABS	0.025%	N87430 001 NOV 01, 1988
> ADD >			
> ADD > AT		0.1%	N87429 001 NOV 01, 1988
> ADD >			
> ADD > AT		0.5%	N87428 001 NOV 01, 1988
> ADD >			

TRYMEX

/AT/	/SAVAGE/LABS/	/0.5%/	/N88198/001/ /MAR/25,/1983/
	a SAVAGE LABS	0.5%	N88198 001 MAR 25, 1983

OINTMENT; TOPICAL

FLUTEX

> ADD >			
> ADD > AT	SYOSSET LABS	0.025%	N87375 001 NOV 01, 1988
> ADD >			
> ADD > AT		0.1%	N87377 001 NOV 01, 1988
> ADD >			
> ADD > AT		0.5%	N87376 001 NOV 01, 1988
> ADD >			

TRIAZOLAM

TABLET; ORAL

HALCION

	/UPJOHN/	/0.5MG/	/N17892/002/ /NOV/15,/1982/
	a UPJOHN	0.5MG	N17892 002 NOV 15, 1982

TRICLOFOS SODIUM

/SOLUTION;ORAL/			
/TRICLOS/			
	/MERRELL/DOW/	/1.5GM/15ML/	/N16830/001/
	a MERRELL DOW	1.5GM/15ML	N16830 001
/TABLET;ORAL/			
/TRICLOS/			
	/MERRELL/DOW/	/750MG/	/N16809/002/
	a MERRELL DOW	750MG	N16809 002

TRIDIHEXETHYL CHLORIDE

/INJECTABLE;/INJECTION/
/PATHILON/
/LEDERLE/LABS/ /10MG/ML/ /N09729/001/
∂ LEDERLE LABS 10MG/ML N09729 001

TRIFLUOPERAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
STELAZINE
AP SK&F CO EQ 2MG BASE/ML N11552 005
TRIFLUOPERAZINE HCL
AP QUAD PHARMS EQ 2MG BASE/ML* N89893 001
OCT 17, 1988

TABLET; ORAL
TRIFLUOPERAZINE HCL
AB BOLAR PHARM EQ 1MG BASE* N85975 001
JUN 23, 1988
AB EQ 2MG BASE* N85976 001
JUN 23, 1988
AB EQ 5MG BASE* N85973 001
JUN 23, 1988
AB EQ 10MG BASE* N88710 001
JUN 23, 1988

TRIMEPRAZINE TARTRATE

CAPSULE, CONTROLLED RELEASE; ORAL
TEMARIL
HERBERT LABS EQ 5MG BASE N11316 004
/SK&F/LABS/ /EQ/5MG/BASE/ /N11316/004/

SYRUP; ORAL
TEMARIL
AA HERBERT LABS EQ 2.5MG BASE/5ML N11316 003
/AA/ /SK&F/LABS/ /EQ 2.5MG BASE/5ML/ /N11316/003/

TABLET; ORAL
TEMARIL
HERBERT LABS EQ 2.5MG BASE N11316 001
/SK&F/LABS/ /EQ/2.5MG/BASE/ /N11316/001/

TRIMETHOPRIM

TABLET; ORAL
TRIMETHOPRIM
AB BARR LABS 100MG N70494 001
JAN 22, 1986
/AA/ /200MG/ /N70495/001/
/MAR/14,/1986/
/∂/ /100MG/ /N70494/001/
/JAN/22,/1986/
∂ 200MG N70495 001
MAR 14, 1986

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
TRIPELENNAMINE HCL
/AA/ /BARR/LABS/ /50MG/ /N80744/001/
∂ BARR LABS 50MG N80744 001

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
/TRIAVIL/
/AA/ /MY K/LABS/ /1.25MG/5ML/ /N87963/001/
/JAN/18,/1983/
∂ MY K LABS 1.25MG/5ML N87963 001
JAN 18, 1983

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
AP QUAD PHARMS 3MG/ML* N89442 001
AUG 12, 1988

URSODIOL

CAPSULE; ORAL
ACTIGALL
∂ CIBA PHARM 150MG N19594 001
DEC 31, 1987
300MG N19594 002
DEC 31, 1987
/DEURSIL/
/SIPHARMEX/ /150MG/ /N19594/001/
/DEC/31,/1987/
/300MG/ /N19594/002/
/DEC/31,/1987/

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	LYPHOCIN			
AP	LYPHOMED	EQ 1GM BASE/VIAL	N62663 002	JUL 31, 1987
AP		EQ 5GM BASE/VIAL‡	N62663 003	JUN 03, 1988
	VANCOCIN HCL			
AP	LILLY	EQ 1GM BASE/VIAL	N60180 002	MAR 21, 1986
AP		EQ 1GM BASE/VIAL	N62476 002	MAR 21, 1986
AP		EQ 1GM BASE/VIAL	N62716 002	MAR 13, 1987
AP		EQ 1GM BASE/VIAL	N62812 002	NOV 17, 1987
AP		EQ 10GM BASE/VIAL	N62812 003	NOV 17, 1987
	VANCOLED			
AP	LEDERLE LABS	EQ 1GM BASE/VIAL‡	N62682 002	MAR 30, 1988
AP		EQ 5GM BASE/VIAL	N62682 004	MAY 11, 1988
AP		EQ 10GM BASE/VIAL‡	N62682 005	MAY 11, 1988
		EQ 2GM BASE/VIAL‡	N62682 003	MAY 11, 1988
	VANCOMYCIN HCL			
AP	ABBOTT LABS	EQ 500MG BASE/VIAL‡	N62911 001	AUG 04, 1988
AP		EQ 1GM BASE/VIAL‡	N62912 001	AUG 04, 1988
AP	ELKINS SINN	EQ 500MG BASE/VIAL‡	N62879 001	AUG 02, 1988
AP		EQ 1GM BASE/VIAL‡	N62879 002	AUG 02, 1988
AP	QUAD PHARMS	EQ 500MG BASE/VIAL‡	N62845 001	JUL 15, 1988
AP		EQ 1GM BASE/VIAL‡	N62845 002	JUL 15, 1988
	VANCOR			
AP	ADRIA LABS	EQ 500MG BASE/VIAL‡	N62956 001	AUG 01, 1988
AP		EQ 1GM BASE/VIAL‡	N62956 002	AUG 01, 1988

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

	CALAN			
	/SEARLE/	/160MG/		/N18817/004/ /FEB 23, 1988/
AB	SEARLE PHARMS	40MG‡	N18817 003	FEB 23, 1988
		160MG	N18817 004	FEB 23, 1988
	ISOPTIN			
AB	KNOLL PHARM	40MG	N18593 003	NOV 23, 1987
	VERAPAMIL HCL			
AB	CORD LABS	80MG‡	N71423 001	MAY 24, 1988
AB		120MG‡	N71424 001	MAY 25, 1988
AB	LEDERLE LABS	80MG‡	N71880 001	APR 05, 1988
AB		120MG‡	N71881 001	APR 05, 1988
AB	MUTUAL PHARM	80MG‡	N71488 001	JAN 13, 1988
AB		120MG‡	N71489 001	JAN 13, 1988

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCREX			
AP	BRISTOL LABS	5MG/VIAL‡	N70867 001	JUL 12, 1988
	VINCRISTINE SULFATE			
AP	BULL LABS	1MG/VIAL‡	N71559 001	APR 11, 1988
AP		2MG/VIAL‡	N71560 001	APR 11, 1988
AP		5MG/VIAL‡	N71561 001	APR 11, 1988
AP	QUAD PHARMS	1MG/VIAL	N71222 001	MAR 07, 1988
AP		2MG/VIAL	N71223 001	MAR 07, 1988
AP		5MG/VIAL	N71937 001	MAR 07, 1988
	VINCRISTINE SULFATE PFS			
AP	BULL LABS	1MG/ML‡	N71484 001	APR 19, 1988

WARFARIN POTASSIUM

>DLT>	/TABLET/ORAL/			
>DLT>	/ATHROMBIN-K/			
>DLT>	/PURDUE/FRDRK/	/5MG/		/N11771/004/
>ADD>	ə PURDUE FRDRK	5MG		N11771 004

WATER FOR INJECTION, STERILE

LIQUID; N/A

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	BAXTER	100%	N18632 002 APR 19, 1988
AP	KENDALL MCGAW	100%	N19633 001 FEB 29, 1988

XYLOSE

POWDER; ORAL

	/XYLOSE/			
/AA/	/LYNE/LABS/	/25GM/BOT/		/N18856/001/ /MAR/26,/1987/
	ə LYNE LABS	25GM/BOT		N18856 001 MAR 26, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL

NEOPAP		
ALCON LABS	120MG	N16401 001
TYLENOL		
MCNEIL CONSUMER	120MG	N17756 002
	650MG	N17756 001

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE

BROMATAPP		
COPLEY PHARM	12MG;75MG	N71099 001 JUL 02, 1987

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, CONTROLLED RELEASE; ORAL

BROMATAPP		
COPLEY PHARM	12MG;75MG	N71099 001 JUL 02, 1987

BUTYL METHOXYDIBENZOYLMETHANE; PADIMATE O

LOTION; TOPICAL

PHOTOPLEX		
HERBERT LABS	3%;7½%	N19459 001 SEP 30, 1988

CHLORPHENIRAMINE MALEATE

CAPSULE, CONTROLLED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE		
CORD LABS	12MG*	N70797 001 AUG 12, 1988

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, CONTROLLED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE		
CENTRAL PHARMS	8MG;120MG*	N19428 001 AUG 02, 1988

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, CONTROLLED RELEASE; ORAL

RESPORAL		
PIONEER PHARMS	6MG;120MG*	N89139 001 JUN 16, 1988

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN DM		
WYETH AYERST LABS	15MG/5ML;6.25MG/5ML*	N11265 003 AUG 11, 1988

HYDROCORTISONE

OINTMENT; TOPICAL

HC (HYDROCORTISONE)		
C&M PHARMA	0.5%	N80481 001

IBUPROFEN

TABLET; ORAL

IBU-TAB 200		
ALRA LABS	200MG*	N71057 001 AUG 11, 1988
IBUPROFEN		
DANBURY PHARMA	200MG*	N71905 001 MAR 08, 1988
INTERPHARM	200MG*	N72199 001 MAY 23, 1988
INVAMED	200MG*	N71807 001 FEB 25, 1988
MEDICOPHARMA	200MG*	N71639 001 FEB 02, 1988
MYLAN PHARMS	200MG*	N71870 001 MAY 05, 1988
PRIVATE FMLTNS	200MG*	N72299 001 JUL 01, 1988
ZENITH LABS	200MG*	N72040 001 APR 29, 1988
NUPRIN		
BRISTOL MYERS	200MG*	N72035 00[illegible] FEB 16, 1988
	200MG*	N72036 001 FEB 16, 1988

IBUPROFEN

TABLET; ORAL
NUPRIN

/UPJOHN/	/200MG/	/N19012/001/ /JUL/29/1987/
	/200MG/	/N19012/001/ /MAY/18/1984/
∂ UPJOHN	200MG	N19012 001 MAY 18, 1984
∂	200MG	N19012 003 JUL 29, 1987

INSULIN SEMISYNTHETIC PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
MIXTARD HUMAN 70/30

NORDISK USA	30 UNITS/ML; 70 UNITS/ML	N19585 001 MAR 11, 1988

INSULIN ZINC SUSP EXTENDED BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN U

/LILLY/	/40/UNITS/ML/	/N19571/001/ /JUN/10/1987/
∂ LILLY	40 UNITS/ML	N19571 001 JUN 10, 1987

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
IMODIUM A-D

MCNEIL CONSUMER	1MG/5ML	N19487 001 MAR 01, 1988

NONOXYNOL-9

SPONGE; VAGINAL
TODAY

/WHI/	/1GM/	/N18683/001/ /APR/01/1983/
WHITEHALL LABS	1GM	N18683 001 APR 01, 1983

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHENERGAN VC

WYETH AYERST LABS	10MG/5ML;6.25MG/5ML	N08604 004 AUG 11, 1988

TIOCONAZOLE

CREAM; TOPICAL
/TROSYD/

/∂/PFIZER/LABS/	/1%/	/N18682/001/ /FEB/18/1983/

TZ-3

∂ PFIZER LABS	1%	N18682 001 FEB 18, 1983

[redacted]

MANNITOL USP; ADENINE

INJECTABLE; INJECTION
OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION
TERUMO 0.9GM/100ML;0.877GM/100ML;
0.525GM/100ML;0.03GM/100ML N 880217
OCT 07, 1988

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
MACRODEX(R)
PHARMACIA INC 6GM/100ML;0.9GM/100ML N 06826

[redacted]

ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG". SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

ORPHAN DRUG EXCLUSIVE APPROVAL STATUS (CODED ODE) APPLIES ONLY TO THE APPROVED OR LICENSED INDICATION(S) FOR WHICH ORPHAN DRUG DESIGNATION HAS BEEN GRANTED PURSUANT TO SECTION 526 OF THE ACT.

FOR THE FOLLOWING DRUG PRODUCTS WITH ORPHAN DRUG EXCLUSIVE APPROVAL STATUS, THE SPONSOR HAS SEVEN YEARS OF EXCLUSIVE APPROVAL FOR THE APPROVED INDICATION BEGINNING ON THE DATE OF NDA, ANTIBIOTIC APPLICATION, OR BIOLOGICAL LICENSE APPROVAL FOR THE DRUG. NO SUBSEQUENT SPONSOR MAY RECEIVE APPROVAL OF AN NDA, BIOLOGICAL LICENSE, PAPER NDA, ANTIBIOTIC APPLICATION, ANDA, OR ABBREVIATED ANTIBIOTIC APPLICATION DURING THE SEVEN YEAR PERIOD FOR THE DRUG AND INDICATION(S) FOR WHICH ODE STATUS IS MAINTAINED UNLESS THE EXCLUSIVE APPROVAL HAS BEEN REVOKED AS DESCRIBED ABOVE OR THE SUBSEQUENT SPONSOR HAS OBTAINED WRITTEN CONSENT FROM THE SPONSOR WHO HAS RECEIVED EXCLUSIVE APPROVAL.

BIOLOGICAL PRODUCTS, ANTIBIOTICS, AND DRUGS THAT HAVE BEEN APPROVED UNDER SECTION 505 OR 507 OF THE ACT OR UNDER SECTION 351 OF THE PUBLIC HEALTH SERVICE ACT FOR MARKETING AND HAVE BEEN GIVEN ORPHAN DRUG EXCLUSIVE APPROVAL WILL BE NOTED BY THE ABBREVIATION ODE IN THE PATENT AND EXCLUSIVITY INFORMATION ADDENDUM. DRUG PRODUCTS THAT HAVE RECEIVED THE WRITTEN PERMISSION OF THE SPONSOR THAT HAS ORPHAN DRUG EXCLUSIVE APPROVAL TO BE APPROVED UNDER SECTION 527(b)(2) OF THE ACT ARE ALSO NOTED BY THE ABBREVIATION ODE IN THE PATENT AND EXCLUSIVITY INFORMATION ADDENDUM. THESE DRUG PRODUCTS DO NOT HAVE ANY EXCLUSIVE APPROVAL RIGHTS OF THEIR OWN, BUT CAN BE MARKETED BECAUSE OF THE CONSENT GIVEN BY THE SPONSOR THAT HAS EXCLUSIVE APPROVAL. THESE PRODUCTS ARE MARKED BY AN (*) NEXT TO THE APPLICANT'S NAME.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL

DRUG PRODUCTS

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME DOSAGE FORM; ROUTE	APPLICANT	APPL. PROD. APPROVAL DATE	EXCLUSIVITY EXP. DATE
LEUCOVORIN CALCIUM EQ 3MG BASE/ML	LEUCOVORIN CALCIUM INJECTABLE; INJECTION	LEDERLE LABS	08107 001 AUG 31, 1988	ODE[1] AUG 31, 1995
LEUCOVORIN CALCIUM EQ 50MG BASE/VIAL	LEUCOVORIN CALCIUM INJECTABLE; INJECTION	LEDERLE LABS	08107 002 AUG 31, 1988	ODE[1] AUG 31, 1995
LEUCOVORIN CALCIUM EQ 100MG BASE/VIAL	LEUCOVORIN CALCIUM INJECTABLE; INJECTION	LEDERLE LABS	08107 004 AUG 31, 1988	ODE[1] AUG 31, 1995
LEUCOVORIN CALCIUM EQ 60MG BASE/VIAL	LEUCOVORIN CALCIUM POWDER FOR RECONSTITUTION; ORAL	LEDERLE LABS	08107 003 AUG 31, 1988	ODE[1] AUG 31, 1995
METHOTREXATE SODIUM EQ 20MG BASE/VIAL	METHOTREXATE INJECTABLE; INJECTION	LEDERLE LABS	11719 001 APR 07, 1988	ODE[2] APR 07, 1995

[1]ODE PERTAINS ONLY TO INDICATION I-79 (SEE EXCLUSIVITY TERMS)
[2]ODE PERTAINS ONLY TO INDICATION I-78 (SEE EXCLUSIVITY TERMS)

ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL

DRUG PRODUCTS

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME DOSAGE FORM; ROUTE	APPLICANT	APPL. PROD. APPROVAL DATE	EXCLUSIVITY EXP. DATE
METHOTREXATE SODIUM EQ 50MG BASE/VIAL	METHOTREXATE INJECTABLE; INJECTION	LEDERLE LABS	11719 003 APR 07, 1988	ODE[2] APR 07, 1995
METHOTREXATE SODIUM EQ 100MG BASE/VIAL	METHOTREXATE INJECTABLE; INJECTION	LEDERLE LABS	11719 006 APR 07, 1988	ODE[2] APR 07, 1995
METHOTREXATE SODIUM EQ 1GM BASE/VIAL	METHOTREXATE INJECTABLE; INJECTION	LEDERLE LABS	11719 009 APR 07, 1988	ODE[2] APR 07, 1995
METHOTREXATE SODIUM EQ 25MG BASE/ML	METHOTREXATE LPF INJECTABLE; INJECTION	LEDERLE LABS	11719 007 APR 07, 1988	ODE[2] APR 07, 1995
METRONIDAZOLE 0.75%	METROGEL GEL; TOPICAL	CURATEK PHARMS	19737 001 NOV 22, 1988	ODE NOV 22, 1995
POTASSIUM CHLORIDE 10MEQ/PACKET	POTASSIUM CHLORIDE POWDER, FOR RECONSTITUTION	UNIV TEXAS	19647 002 OCT 13, 1988	ODE AUG 30, 1992
POTASSIUM CHLORIDE 20MEQ/PACKET	POTASSIUM CHLORIDE POWDER, FOR RECONSTITUTION	UNIV TEXAS	19647 001 OCT 13, 1988	ODE AUG 30, 1992
TIOPRONIN 100MG	TIOPRONIN TABLET; ORAL	UNIV TEXAS	19569 001 AUG 11, 1988	ODE AUG 11, 1995

[2]ODE PERTAINS ONLY TO INDICATION I-78 (SEE EXCLUSIVITY TERMS)

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 1988 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFN-250, ROOM 17B-06, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ACETOHEXAMIDE (TABLET)	NOV 15, 1985	AUG 01, 1988
ALBUTEROL; METAPROTERENOL SULFATE (METERED DOSE INHALER)	AUG 25, 1988	
AMOXAPINE (TABLET)	SEP 10, 1987	AUG 05, 1988
ATENOLOL (TABLET)	OCT 06, 1988	
CARBAMAZEPINE (TABLET)	JAN 01, 1988	
CLINDAMYCIN (CAPSULE)	MAY 31, 1988	
CONJUGATED ESTROGEN (TABLET)*	DEC 27, 1988	
CYCLOBENZAPRINE HYDROCHLORIDE (TABLET)	JAN 25, 1988	
DOXYCYCLINE HYCLATE (CAPSULE AND TABLET)	APR 11, 1988	
ERYTHROMYCIN (CAPSULE, ENTERIC COATED PELLETS)	SEP 21, 1988	
FENOPROFEN (CAPSULE AND TABLET)	AUG 27, 1987	FEB 03, 1988
INDOMETHACIN (CAPSULE)	JAN 27, 1988	
LEUCOVORIN CALCIUM (TABLET)	APR 28, 1987	AUG 04, 1988
MESTRANOL; NORETHYNODREL (TABLET)	MAY 13, 1988	
METAPROTERENOL SULFATE (TABLET)	MAR 18, 1988	
NORETHINDRONE; ETHINYL ESTRADIOL (TABLET)	MAR 18, 1988	
PRAZEPAM (CAPSULE AND TABLET)	JUL 26, 1988	
RIFAMPIN (CAPSULE)	SEP 08, 1988	
TIMOLOL MALEATE (TABLET)	AUG 09, 1988	

*THE METHODOLOGY IN THE BIOPHARMACEUTICAL AVAILABILITY GUIDANCE IS NO LONGER ACCEPTED BY THE AGENCY.

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETYLCYSTEINE SOLUTION; INHALATION	20%	88 P-0237/CP	DEY LABS	NEW STRENGTH	APPROVED NOV 29, 1988
ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 5MG	87 P-0376/ CP0002	ANABOLIC	NEW STRENGTH	APPROVED FEB 12, 1988
ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	650MG 5MG	87 P-0376/CP	ANABOLIC	NEW STRENGTH	APPROVED FEB 12, 1988
CHLORHEXIDINE GLUCONATE SPONGE; TOPICAL	150MG	88 P-0295/CP	BRIAN PHARMS	NEW STRENGTH	APPROVED NOV 03, 1988
CHLORHEXIDINE GLUCONATE SPRAY; TOPICAL	0.5%	88 P-0036/CP	ARENT, FOX, KINTNER, PLOTKIN & KAHN	NEW DOSAGE FORM	APPROVED AUG 19, 1988
CHLORZOXAZONE CAPSULE; ORAL	500MG	82 N-0032/ CP0006	MIKART	NEW DOSAGE FORM	APPROVED JAN 13, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CISPLATIN INJECTABLE; INJECTION	1MG/ML (10ML/VIAL) (50ML/VIAL) (100ML/VIAL)	87 P-0421/CP	BULL LABS	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 29, 1988
CISPLATIN INJECTABLE; INJECTION	1MG/ML (20ML/VIAL)	88 P-0010/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	APPROVED APR 01, 1988
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	20MG/ML (500ML/CONTAINER)	88 P-0011/CP	BAXTER HLTHCARE	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUN 10, 1988
FLUOROURACIL INJECTABLE; INJECTION	50MG/ML (5ML/VIAL)	88 P-0052/CP	BEN VENUE LABS	NEW STRENGTH	APPROVED MAR 21, 1988
HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE SOFT GELATIN CAPSULE; ORAL	1.5MG 5MG	88 P-0061/CP	KLEINFELD, KAPLAN AND BECKER	NEW DOSAGE FORM	APPROVED MAY 12, 1988
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML 40MG/5ML	87 P-0399/CP	BURDITT, BOWLES, RADZIUS AND RUBERRY	NEW DOSAGE FORM	APPROVED FEB 16, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML 80MG/5ML	87 P-0399/CP	BURDITT, BOWLES, RADZIUS AND RUBERRY	NEW DOSAGE FORM	APPROVED FEB 16, 1988
HYDROCHLOROTHIAZIDE; TRIAMTERENE TABLET; ORAL	25MG 50MG	87 P-0335/CP	PAR PHARM	NEW DOSAGE FORM	APPROVED FEB 26, 1988
LEUCOVORIN CALCIUM SOLUTION; ORAL	EQ 1MG BASE/ML	88 P-0149/CP	ROXANE LABS	NEW DOSAGE FORM	APPROVED JUL 25, 1988
MEPERIDINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (50ML/CONTAINER)	88 P-0008/CP	LYPHOMED	NEW STRENGTH	APPROVED APR 01, 1988
METOCLOPRAMIDE HYDROCHLORIDE INTENSOL CONCENTRATE; ORAL	10MG/ML	88 P-0164/CP	ROXANE LABS	NEW STRENGTH	APPROVED JUN 28, 1988
NIFEDIPINE CAPSULE; ORAL	10MG	88 P-0072/ CP0002	MARTEC PHARMS	NEW DOSAGE FORM	APPROVED MAY 11, 1988
NIFEDIPINE CAPSULE; ORAL	20MG	88 P-0072/CP	MARTEC PHARMS	NEW DOSAGE FORM	APPROVED MAY 11, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
PHENYLPROPANOLAMINE HYDROCHLORIDE FILM, CONTROLLED RELEASE; PERCUTANEOUS	150MG	88 P-0265/CP	BIO AMERICAN	NEW DOSAGE FORM NEW STRENGTH NEW INDICATION	APPROVED OCT 07, 1988
PHENYTOIN SODIUM INJECTABLE; INJECTION	100MG/VIAL 250MG/VIAL	87 P-0367/CP	LYPHOMED	NEW DOSAGE FORM	APPROVED FEB 16, 1988
PREDNISOLONE SODIUM PHOSPHATE SOLUTION; ORAL	EQ 5MG BASE/ML	88 P-0235/CP	PAN AM PHARMS	NEW STRENGTH	APPROVED AUG 24, 1988
QUINIDINE GLUCONATE TABLET, CONTROLLED RELEASE; ORAL	648MG	87 P-0276/CP	FOREST LABS	NEW STRENGTH	APPROVED NOV 22, 1988
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER INJECTABLE; INJECTION	900MG/100ML (100ML/CONTAINER)	87 P-0391/CP	LYPHOMED	NEW STRENGTH	APPROVED AUG 11, 1988
STERILE WATER IN PLASTIC CONTAINER INJECTABLE; INJECTION	100% (100ML/CONTAINER)	87 P-0392/CP	LYPHOMED	NEW STRENGTH	APPROVED AUG 11, 1988
THEOPHYLLINE CAPSULE, CONTROLLED RELEASE; ORAL	450MG	88 P-0119/CP	RIKER LABS	NEW STRENGTH	APPROVED MAY 11, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
THEOPHYLLINE CAPSULE, CONTROLLED RELEASE; ORAL	500MG	88 P-0226/CP	SAVAGE LABS	NEW STRENGTH	APPROVED AUG 25, 1988
THEOPHYLLINE SOLUTION; ORAL	160MG/15ML	88 P-0301/CP	FLEMING	NEW STRENGTH	APPROVED NOV 04, 1988
THIOTEPA (WITH DILUENT) INJECTABLE; INJECTION	15MG/VIAL	87 P-0382/CP	LYPHOMED	NEW DOSAGE FORM	APPROVED MAY 12, 1988
VERAPAMIL HYDROCHLORIDE CAPSULE, CONTROLLED RELEASE; ORAL	120MG 240MG	87 P-0233/CP	SEARLE	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 26, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
BENZOYL METRONIDAZOLE SUSPENSION; ORAL	200MG/5ML	85 P-0258/CP	APKON LABS	NEW INGREDIENT (NEW ESTER)	DENIED MAR 19, 1986
BROMPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE SYRUP; ORAL	2MG/5ML 2.5MG/5ML 12.5MG/5ML	85 P-0237/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
BROMDIPHENHYDRAMINE HYDROCHLORIDE; HYDROCODONE BITARTRATE SOLUTION; ORAL	12.5MG/5ML 2.5MG/5ML	85 P-0255/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
BROMDIPHENHYDRAMINE HYDROCHLORIDE; HYDROCODONE BITARTRATE SYRUP; ORAL	12.5MG/5ML 2.5MG/5ML	85 P-0255/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
CYCLOBENZAPRINE HYDROCHLORIDE TABLET; ORAL	15MG	86 P-0386/CP	CENTRAL PHARMS	NEW STRENGTH	DENIED AUG 15, 1988
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	100MG/ML (1ML/VIAL) (2ML/VIAL)	87 P-0283/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	DENIED JAN 21, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	500MG/ML (1ML/VIAL) (2ML/VIAL) (4ML/VIAL)	87 P-0283/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	DENIED JAN 21, 1988
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, SUSTAINED RELEASE; ORAL	75MG	87 P-0355/CP	PARKE DAVIS	NEW DOSAGE FORM NEW STRENGTH	DENIED MAY 11, 1988
HYDROCODONE BITARTRATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE SYRUP; ORAL	1.66MG/5ML 5MG/5ML 6.25MG/5ML	85 P-0389/CP	UAD LABS	NEW COMBINATION	DENIED MAY 11, 1988
HYDROCODONE BITARTRATE; PROMETHAZINE HYDROCHLORIDE SYRUP; ORAL	2.5MG/5ML 6.25MG/5ML	85 P-0256/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
MAGNESIUM ASCORBATE INJECTABLE; INJECTION	10% 20%	88 P-0200/CP	RIM CONSULTING	NEW INGREDIENT	DENIED JUN 10, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (50ML/VIAL) (75ML/VIAL) (100ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-12 BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13 INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14 BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15 SINGLE DAILY DOSE OF 25MG/37.5MG

NEW INDICATION

I-19 CHOLANGIOPANCREATOGRAPHY
I-72 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-73 FOLLICULAR STIMULATION IN IN VITRO FERTILIZATION
I-74 MANAGEMENT OF CONGESTIVE HEART FAILURE
I-75 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-76 HERNIOGRAPHY
I-77 KNEE ARTHROGRAPHY
I-78 HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-79 RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-80 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-81 TREATMENT OF RHEUMATOID ARTHRITIS
I-82 ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-83 TREATMENT OF LIVER FLUKES

EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-26	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-27	METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-28	METHOD FOR IMPROVING MEMORY IN MAMMALS
U-29	METHOD FOR TREATING AMNESIA
U-30	METHOD OF POTENTIATING CODEINE ANALGESIA IN MAMMALS
U-31	USE IN LUNG SCANNING PROCEDURES
U-32	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-33	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-34	TREATMENT OF INFLAMMATION

	APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	3705233	DEC 05, 1989			
			3644353	FEB 22, 1989		NDF	MAY 04, 1991
	18116 002	AMCINONIDE; CYCLOCORT	4158055	JUN 12, 1996	U-34		
	18498 001	AMCINONIDE; CYCLOCORT	4158055	JUN 12, 1996	U-34		
	19716 001	BETAMETHASONE DIPROPIONATE; DIPROLENE				NP	AUG 01, 1991
	18644 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	MAR 26, 2002			
	18644 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	MAR 26, 2002			
	18644 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	MAR 26, 2002			
	19459 001	BUTYL METHOXYDIBENZOYLMETHANE; PHOTOPLEX	4387089	JUN 07, 2000		NP	SEP 30, 1991
>ADD>	71621 001	CHOLESTYRAMINE; CHOLYBAR	4778676	OCT 18, 2005			
>ADD>	71739 001	CHOLESTYRAMINE; CHOLYBAR	4778676	OCT 18, 2005			
	17920 002	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
	17920 003	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
	17920 004	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
	17920 005	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
	17924 001	CIMETIDINE HYDROCHLORIDE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
			3950333	APR 13, 1993		D-12	APR 30, 1989
>ADD>	18057 004	CISPLATIN; PLATINOL-AQ	4310515	JAN 12, 1999			
>ADD>			4177263	DEC 04, 1996			
	18891 001	CLONIDINE; CATAPRES-TTS-1	4201211	MAY 06, 1997			
			4060084	JUN 28, 1994			
			3996934	JUL 29, 1992			
	18891 002	CLONIDINE; CATAPRES-TTS-2	4201211	MAY 06, 1997			
			4060084	JUN 28, 1994			
			3996934	JUL 29, 1992			
	18891 003	CLONIDINE; CATAPRES-TTS-3	4201211	MAY 06, 1997			
			4060084	JUN 28, 1994			
			3996934	JUL 29, 1992			
	19201 001	DICLOFENAC SODIUM; VOLTAREN	3652762	MAR 28, 1989		NCE	JUL 28, 1993
	19201 002	DICLOFENAC SODIUM; VOLTAREN	3652762	MAR 28, 1989		NCE	JUL 28, 1993
	19201 003	DICLOFENAC SODIUM; VOLTAREN	3652762	MAR 28, 1989		NCE	JUL 28, 1993
	18998 001	ENALAPRIL MALEATE; VASOTEC				I-74	JUN 24, 1991
	18998 002	ENALAPRIL MALEATE; VASOTEC				I-74	JUN 24, 1991
	18998 003	ENALAPRIL MALEATE; VASOTEC				I-74	JUN 24, 1991
	18998 005	ENALAPRIL MALEATE; VASOTEC	4374829	FEB 22, 2000		NCE	DEC 24, 1990
						I-74	JUN 24, 1991
	19309 001	ENALAPRILAT; VASOTEC	4374829	FEB 22, 2000		NDF	FEB 09, 1991
	18981 002	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32		
	18981 003	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32		
	18981 004	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32		

	APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19386 001	ESMOLOL HYDROCHLORIDE; BREVIBLOC	4593119	JUN 03, 2003		NCE	DEC 31, 1991
			4387103	JUN 07, 2000	U-16		
	19462 001	FAMOTIDINE; PEPCID				I-80	OCT 17, 1991
	19462 002	FAMOTIDINE; PEPCID				I-80	OCT 17, 1991
	19510 001	FAMOTIDINE; PEPCID				I-80	OCT 17, 1991
	19527 001	FAMOTIDINE; PEPCID				I-80	OCT 17, 1991
	18830 003	FLECAINIDE ACETATE; TAMBOCOR	4005209	JAN 25, 1996		NS	JUN 03, 1991
			3900481	AUG 19, 1992		NCE	OCT 31, 1990
	18830 004	FLECAINIDE ACETATE; TAMBOCOR	4005209	JAN 25, 1996			
			3900481	AUG 19, 1992		NCE	OCT 31, 1990
	19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTHE/FS				NDF	FEB 03, 1991
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4683235	JUL 28, 2004	U-30		
			4647591	MAR 03, 2004	U-28		
			4647591	MAR 03, 2004	U-29		
			4626549	DEC 02, 2003	U-26		
			4626549	DEC 02, 2003	U-27		
			4194009	APR 19, 1994			
	18766 002	FLURBIPROFEN; ANSAID	3793457	FEB 19, 1993		NCE	DEC 31, 1991
			3755427	AUG 28, 1990		NDF	OCT 31, 1991
	18766 003	FLURBIPROFEN; ANSAID	3793457	FEB 19, 1993		NCE	DEC 31, 1991
			3755427	AUG 28, 1990		NDF	OCT 31, 1991
	19404 001	FLURBIPROFEN SODIUM; OCUFEN	3793457	FEB 19, 1993			
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4647447	MAR 03, 2004		NCE	JUN 02, 1993
	18422 001	GEMFIBROZIL; LOPID	3674836	JAN 04, 1993			
	18422 002	GEMFIBROZIL; LOPID	3674836	JAN 04, 1993			
	18061 001	HYDROCHLOROTHIAZIDE; TIMOLIDE 10-25	3655663	APR 11, 1989		D-2	FEB 03, 1991
	19129 003	HYDROCHLOROTHIAZIDE; MAXZIDE-25				D-15	MAY 13, 1991
	18956 002	IOHEXOL; OMNIPAQUE 240				I-19	JUL 29, 1991
						I-60	JUL 29, 1991
						I-75	JUL 29, 1991
						I-76	JUL 29, 1991
						I-77	JUL 29, 1991
	18956 003	IOHEXOL; OMNIPAQUE 300	4021481	MAY 03, 1994		I-55	FEB 01, 1988
						I-58	FEB 01, 1988
						I-60	JUL 29, 1991
						I-77	JUL 29, 1991
	18956 004	IOHEXOL; OMNIPAQUE 350				I-56	MAY 24, 1991
						I-77	JUL 29, 1991
>ADD>	18956 005	IOHEXOL; OMNIPAQUE 140	4396597	JUL 14, 1998		I-82	NOV 30, 1991
>ADD>			4250113	DEC 26, 1999		NCE	DEC 26, 1990
>ADD>			4021481	MAY 03, 1994		NS	NOV 30, 1991

	APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19085 001	IPRATROPIUM BROMIDE; ATROVENT	3681500	AUG 01, 1991		NCE	DEC 29, 1991
	08107 001	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	AUG 31, 1995
						I-79	AUG 31, 1995
	08107 002	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	AUG 31, 1995
						I-79	AUG 31, 1995
	08107 003	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	AUG 31, 1995
						I-79	AUG 31, 1995
	08107 004	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	AUG 31, 1995
						I-79	AUG 31, 1995
	19777 001	LISINOPRIL; ZESTRIL	4374829	FEB 22, 2000		NCE	DEC 29, 1992
	19777 002	LISINOPRIL; ZESTRIL	4374829	FEB 22, 2000		NCE	DEC 29, 1992
	19777 003	LISINOPRIL; ZESTRIL	4374829	FEB 22, 2000		NCE	DEC 29, 1992
	19487 001	LOPERAMIDE HYDROCHLORIDE; IMODIUM A-D	3714159	JAN 30, 1990			
	19643 003	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		NCE	AUG 31, 1992
	18006 001	MECLOFENAMATE SODIUM; MECLOMEN				I-68	AUG 30, 1991
	18006 002	MECLOFENAMATE SODIUM; MECLOMEN				I-68	AUG 30, 1991
	08085 002	METHOTREXATE SODIUM; METHOTREXATE				I-81	OCT 31, 1991
	11719 001	METHOTREXATE SODIUM; METHOTREXATE				ODE	APR 07, 1995
						I-78	APR 07, 1995
	11719 003	METHOTREXATE SODIUM; METHOTREXATE				ODE	APR 07, 1995
						I-78	APR 07, 1995
	11719 006	METHOTREXATE SODIUM; METHOTREXATE				ODE	APR 07, 1995
						I-78	APR 07, 1995
	11719 007	METHOTREXATE SODIUM; METHOTREXATE LPF				ODE	APR 07, 1995
						I-78	APR 07, 1995
	11719 009	METHOTREXATE SODIUM; METHOTREXATE				ODE	APR 07, 1995
						I-78	APR 07, 1995
	09048 001	METHOXSALEN; 8-MOP				I-72	MAR 23, 1991
>ADD>	19737 001	METRONIDAZOLE; METROGEL				NDF	NOV 22, 1991
>ADD>						ODE	NOV 22, 1995
	18654 001	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		NCE	DEC 20, 1990
	18654 002	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		NCE	DEC 20, 1990
>ADD>	19501 001	MINOXIDIL; ROGAINE	4596812	FEB 13, 1996			
>ADD>			4139619	FEB 13, 1996		NDF	AUG 17, 1991
	19516 002	MORPHINE SULFATE; MS CONTIN				NDF	MAY 29, 1990
	18677 001	NABILONE; CESAMET	4087545	MAY 02, 1997	U-7		
	19599 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 1998		NCE	MAR 01, 1993
	19508 001	NIZATIDINE; AXID	4760075	MAY 03, 2000	U-33		
			4382090	MAY 03, 2000	U-33		
			4375547	MAR 01, 2000		NCE	APR 12, 1993
	19508 002	NIZATIDINE; AXID	4760075	MAY 03, 2000	U-33		
			4382090	MAY 03, 2000	U-33		
			4375547	MAR 01, 2000		NCE	APR 12, 1993

	APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19667 001	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2000		NCE	OCT 21, 1993
	19667 002	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2000		NCE	OCT 21, 1993
	19667 003	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2000		NCE	OCT 21, 1993
	19009 001	PIRBUTEROL ACETATE; MAXAIR	4175128	NOV 20, 1996			
			3786160	JAN 15, 1993			
	19561 003	POTASSIUM CHLORIDE; MICRO-K LS	3700681	OCT 24, 1989		NCE	DEC 30, 1991
	19647 001	POTASSIUM CITRATE; POTASSIUM CITRATE	4259315	MAR 31, 1998			
	19647 002	POTASSIUM CITRATE; POTASSIUM CITRATE				ODE	AUG 30, 1992
>ADD>	18714 001	PRAZIQUANTEL; BILTRICIDE				ODE	AUG 30, 1992
	17535 002	PROBUCOL; LORELCO				I-83	NOV 09, 1991
	17881 001	TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT; TECHNETIUM TC 99M	3862332	JAN 21, 1992			
			3872226	MAR 18, 1992			
	19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	3863004	JAN 28, 1992	U-31		
			4251532	FEB 17, 2000	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19641 001	TERCONAZOLE; TERAZOL 3	4358449	NOV 09, 1999		NCE	DEC 31, 1992
						NDF	MAY 24, 1991
	19569 001	TIOPRONIN; TIOPRONIN				NCE	AUG 11, 1993
						ODE	AUG 11, 1995
	18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
			4215104	JUL 29, 1997			
	19049 001	TRETINOIN; RETIN-A	3906108	SEP 16, 1992			
			3729568	APR 24, 1990			
	19415 002	UROFOLLITROPIN; METRODIN				I-73	MAR 01, 1991
	18817 003	VERAPAMIL HYDROCHLORIDE; CALAN				I-50	DEC 16, 1989
						I-51	DEC 16, 1989
	18817 004	VERAPAMIL HYDROCHLORIDE; CALAN				I-50	DEC 16, 1989
						I-51	DEC 16, 1989

New 9th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

9TH EDITION

Superintendent of Documents Subscriptions Order Form

Order Processing Code
* 6381

Charge your order. It's easy! MasterCard VISA CHOICE

☐ **YES,** please send me the following indicated subscriptions:

_____ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS,** APDP, and monthly Cumulative Supplements, for $87.00 per year.

1. The total cost of my order is $ _____. All prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

Please Type or Print

2. _____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

3. **Please choose method of payment:**

☐ Check payable to the Superintendent of Documents

☐ GPO Deposit Account ☐☐☐☐☐☐☐☐–☐

☐ VISA, CHOICE or MasterCard

☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____ **Thank you for your order!**
(Credit card expiration date)

_____
(Signature) 11/88

4. **Mail To:** Superintendent of Documents, Government Printing Office, Washington, D.C. 20402-9371.

81